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Diabetes mellitus (DM) is a metabolic disease characterized by high levels of blood 
glucose resulting from defects in insulin production or action. A world-wide increase in 
the diabetes rate is projected to reach pandemic levels over the next 10-20 years. Current 
data shows that high numbers of the population in Saudi Arabia suffer from diabetes and 
prediabetes. Non-traditional treatments of diabetes from medicinal plants has shown 
potential antidiabetic activity. A considerable percentage of the population still prefer or 
use medicinal plants as a treatment or supplement to traditional medicine. Cissus 
rotundifolia (family Vitaceae) is a known plant in southwestern Saudi Arabia used by 
people in the region to treat skin diseases, burns and diabetes. The chemical and 
biological characteristics of Cissus rotundifolia’s active compounds are unknown. The 
aim of this study to investigate the chemical and biological properties of this medicinal 
plant using bio-assay guided separation. Aqueous methanol extract of Cissus rotundifolia 
was fractionated by partitioning against hexane and ethyl acetate. Methanol, ethyl acetate 
and hexane extracts were then screened for antidiabetic activity using an alpha-
glycosidase assay at a concentration of 12.5-50 mg/ml. Methanol extract showed a 
significant alpha-glucosidase inhibition percent of 58-95%. Further, LC separation 
 xvi 
afforded six compounds isolated and characterized using 1H-NMR, 13C-NMR and 
2DNMR. Two of the isolated compounds: 3 and 4 (1,4-dimethyl 2-hydroxybutanedioate 
and 3-hydroxy-4-methoxy-4-oxobutanoate, respectively) showed a significant inhibition 
of alpha-glycosidase enzyme in the range of 25% to 50% at a concentration range from 
1.00 – 0.25 mg/ml. Also, since glucose uptake is considered one of the main pathways to 
control blood sugar levels, the fractions and the isolated compounds were investigated for 
their glucose uptake activity. Glucose uptake assay results showed that the ethyl acetate 
fraction has a significant uptake activity. The isolated compounds 3 and 4 showed 
increased of glucose uptake activity reach of 19 % and 25%, respectively, with Insulin 
used as the positive control. Structural similarities of isolated compounds to malate which 
is a main substrate of citric acid cycle, prompted us to build hypothesis that these 
compounds might interfere with gluconeogenesis process through inhibition of the citric 
acid cycle. Molecular modeling study of isolated compounds and their analogs targeting 
all enzymes involve in citric acid cycle was conducted to examine potential binding 
affinity of these compounds toward proteins in citric acid cycle. Docking study showed 
analogs S-2-aminosuccininamide (AN21), levulinic acid and isolated compound SAA4 
exhibiting high affinity binding to the fumarase enzyme that plays an important role in 
citric acid cycle. Docking study clearly suggest compound SAA4 has potential inhibition 
of gluconeogenesis.  In conclusion, this study authenticated that C. rotundifolia potential 
antidiabetic activity through inhibition of intestinal α-glucosidase, induction of glucose 





1 CHAPTER ONE: GENERAL INTRODUCTION AND BACKGROUND 
1.1 Natural products 
1.1.1 Natural product overview 
Plants produce different types of metabolites (primary and secondary) which 
regulate multiple functions.1 Primary metabolites are synthesized by plants to maintain 
biochemical processes such as growth and development. Primary metabolites include 
amino acids, simple sugars, nucleic acids, and lipids. On the other hand, secondary 
metabolites are chemicals synthesized by plants to perform specific functions that are not 
necessary for biochemical processes. Alkaloid, terpenoid and phenolics are the major 
groups of compounds in plants (figure 1). Secondary metabolites are chemicals 
synthesized by living organisms to perform certain functions that are not specifically for 
biochemical processes; for example, defenses against herbivory or pollinator attraction. 2 
Natural products are defined as organic compounds originating from living organisms 
such as animals, plants and microorganisms.3 However, the term "natural products" is 
established from secondary metabolites.3 According to the definition mentioned 
previously, natural products refers to whole organisms such as plants; animals; parts of 
organisms like leaves, roots or flowers; extracts from organisms; isolated animal organs; 
or pure compounds isolated from organism extracts such as flavonoid, terpenoid, alkaloid 
or steroid.3  
1.1.2  Natural product history as source of novel medicine 
Plants are always very rich sources of drugs, and the majority of currently 
available drugs on the market have been derived—directly or indirectly—from plants.4, 5 
 2 
In fact, plants have actually provided a starting point for the synthesis of over 50% of 
available used pharmaceutical drugs.6 For example, Glucophage® (metformin), one of 
the cheapest and most popular oral hypoglycemic drugs available nowadays on the 
market, is derived from Galega Officinalis (Fabaceae).3 Based on ethno-botanical data, 
about 800 plant species show hypoglycemic activity and more than 1,000 plants 
worldwide have been used as folk medicine to control of type-II diabetes.7 Momordica 
charantia, commonly known as bitter melon, is one of the most common plants used to 
treat diabetes in the world, particularly in Asia, South America and India. Folk medicine 
of various native communities has long used medicinal plants to treat diabetes. 
Examining this practice provides a new area of research on the antidiabetic effect of 
medicinal plants.8 Natural products, especially medicinal plants, have played a very 
important role in treating human disease, and the use of medicinal plants has been dated 
back to ancient times.3 Natural products are used in the treatment of numerous health 
conditions. Further, the use of natural products for medicinal purposes by countries such 
as India, China and South Africa has been practiced for thousands of years.3 According to 
the World Health Organization (WHO), 65% of the global population is dependent on 
natural products for healthcare.3 In China, for example, more than 7,295 plant species are 
used as sources of medicinal agents.3 Today, in developed countries, 70% to 80% of the 
population uses some form of alternative or complementary medicine.3 Moreover, herbal 
medicine is one of the most popular forms of traditional medicine in addition to being 
ranked as the most lucrative industry in the international marketplace.3 Various cultures 
worldwide still rely on herbal medicines with approximately 38% of American adults 
using alternative medicines.9 People depend on alternative or complementary medicine 
 3 
primarily to manage side effects of pharmaceutical drugs or turn to it as an alternative 
when pharmaceutical options do not provide relief from disease. The drug discovery field 
depends on natural products for new medicines especially because existing therapies have 
many side effects that result in the recall of drugs.10 Therefore, there is a need to study 
these medicinal plants in order to give scientific authentication to the proper use of these 
plants and remove any medications that may cause harm to patients. It is encouraging to 
see that, recently, many researchers became interested in giving scientific authentication 
to the activity of plants used in traditional medicine around the world.  
1.1.3 Sources of natural products 
Sources of natural products are numerous and may include plants, marines, 
animals and microbes. Plants are the richest source of natural products, and the use of 
certain plants can be seen in herbal medicine throughout human history.6 The current 
predicted number of plant species worldwide is around 250,0000.11 However, a limited 
number of these plant species have been screened for medicinal properties. In fact, less 
than 10% of medicinal plant species have been investigated and validated for their 
medical properties.12 Furthermore, un-investigated plants could be a major source in drug 
discovery. Therefore, the search for effective, safe, affordable and convenient agents 
from medicinal plants has continued to be an important area of investigation. Numerous 
drugs currently available on the market have been derived from plants either directly or 
indirectly.13, 14 Examples include the narcotic analgesic morphine from Papaver 
somniferum, the anticancer drug vincristine from Vinca rosea, the antimalarial drug 
artemisinin from Artemisia annua, the anticancer drug Taxol from Taxus brevifolia, the 
 4 
antibiotic penicillin from Penicillium ssp and the most common antidiabetic available 









1.1.4   Drug discovery from natural product 
Compounds isolated from natural products have a significant role in the discovery 
and developments of new medicines.7 In spite of combinatorial chemistry’s proposals of 
new drugs, natural products still remain the main sources of drug discovery and are 
involved in the most used clinical drug available today.8 According to a study of all new 
chemical entities (1,355 total) accepted as new medicines in the period time between 
January 1981 and December 2010, 26% are natural products or their derivatives, and 
another 24% are synthetic natural product mimics or have natural product 
pharmacophores. Also, 15% are biological macromolecules such as peptides, 6% are 
vaccines and 29% are totally synthetic (Figure 1-2). 15 These data obviously prove that, as 
a minimum, 50% of all these new drugs are related to natural products. In 1999, one of 
the top twenty best-selling, non-protein medicines (simvastatin, pravastatin, lovastatin, 
augmentin, enalapril, atorvastatin, ciprofloxacin, cyclosporine clarithromycin and) were 
originally natural products or their synthetic derivatives, with expected sales exceeding 
$16 billion annually.16 In addition to the important of natural products as sources of drug 
leads and the significant role of natural products in drug discoveries, natural products 
have greater chemical novelty and large-scale structural diversity than any other drug 
sources.16  
 About 40% of the natural products recorded in the natural products database 
(Dictionary of Natural Products, Chapman & Hall) are not derived from synthetic 
chemistry.16 On the other hand, a variety of tools have been established to accelerate the 
drug discovery process. Among the most popular and frequently used tools in drug 
discovery are bioassay-guided fractionation and computer-aided drug design. 
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Figure 1-2: Natural products as sources of new drugs over 30 years (1981 to 2010)  Reprinted 
from 17.  
1.1.4.1 Bioassay-guided fractionation  
The bioassay-guided fractionation method is frequently used in drug discovery 
involving natural products because of its ability to connect the chemical profile of 
extracts and fractions to specific biological tests.18 Bioassay-guided fractionation is a 
process of generating a fractionated and refractionated extract using several analytical 
methods until a pure biologically active compound is isolated.19 This technique begins 
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with fractionating the crude mixture into several fractions, then each fraction is estimated 
using different bioassay systems. Only biologically active fractions are exposed to a 
further fractionation process. The process of  fractionation and biological assessment 
continues until a pure biologically active compound is isolated.3 The general steps of 
bioassay-guided fractionation are presented in Figure 1-3.  
 
Figure 1-3: The general steps of bioassay-guided fraction.3 
 
1.1.4.2 Computer-aided drug design  
Connecting computational power and progressive technologies to combined 
chemical and biological fields has extremely accelerated drug discovery, design, 
development and optimization.20 Computer Aided Drug Design (CADD) is an approach 
that plays an essential role in drug discovery and has increasingly become widespread in 
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the pharmaceutical industry.20 Practically, Computer Aided Drug Design (CADD) refers 
to diverse terms like computational drug design, computer–aided molecular design 
(CAMD), rational drug design, computer–aided rational drug design, computer–aided 
molecular modeling (CAMM) and in silico drug design.20 Computer Aided Drug Design 
(CADD) is generally expressed using computational tools and resources for the storage, 
management, analysis and modeling of compounds.20 The fundamental goal of CADD “is 
to discover hits (active drug molecules), determine leads (the most likely candidates for 
further evaluation), and modify leads i.e. transform biologically active molecules into 
suitable drugs by improving their properties such as physicochemical, pharmaceutical, 
ADMET/PK (pharmacokinetic) properties.”20 Several computational tools are used in the 
computer-aided drug design process; these include ligand and structure-based 
pharmacophore modeling, homology modeling, docking and scoring, ligand-based 
quantitative structural activity relationship development, molecular dynamics simulation, 
similarity-diversity analyses, designing and enumerating virtual libraries, virtual high-
throughput screening and computational prediction of absorption, distribution, 
metabolism, elimination (ADME) properties.21 There are two types of CADD approaches 
based on the availability of the experimental 3D structures of the target proteins. The 
ligand-based drug design approach, such as pharmacophore analysis and Quantitative 
Structure Activity Relationship (QSAR), can be used when protein structures are 
unknown. Otherwise, the structure-based approaches, for example molecular docking, 
can be utilized when protein structures are known.17  
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1.1.4.2.1 Molecular docking  
Molecular docking is the most commonly used strategy in the structure-based 
drug design approach. It is also used in the drug discovery method to find the highest 
matches between a receptor and a ligand.17 The molecular docking process involves 
predicting the conformations and orientation of a compound in the active site of target 
macromolecules and detecting the preferred configurations and conformations of 
molecules interacting therein.17 The major objectives of molecular docking are to perfect 
structural modeling and make a suitable prediction of activity.3 Furthermore, molecular 
docking has been used in different stages of the drug discovery pipeline, such as 
quantitative structure activity relationship, virtual combinatorial library generation, lead 
optimization and the discovery of a potential lead through virtual screening.22 In addition, 
the application of molecular molding has been used to study of the physico-chemical 
parameters of the ligand, involving absorption, distribution, metabolism and 
elimination/toxicity using different applications and programs.20 In molecular modeling, 
the scoring function is commonly used to determine the interaction between the ligands 
and the binding sites of target macromolecules. For example, using one of the scoring 
methods employed in virtual high throughput screening, a virtual library of a significant 
number of ligands docked into the binding sites of target macromolecules is created, 
which are then scored based on their affinity to the binding sites of the target 
macromolecules.21 There are large numbers of docking programs that have been 
developed and are used in the drug discovery process, including AutoDock, DOCK, 
ArgusDock and FTDock.21 OpenEye Software sets (Fast Rigid Exhaustive Docking 
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(FRED), make Receptor, Omega, FRED and VIDA) were used to run the molecular 
docking studies. 
 
1.2 Saudi flora 
Saudi Arabia is a Middle Eastern country with a population of more than 25 million 
people. In Saudi Arabia, people live in both urban and rural areas and quit sectors are still 
use traditional natural medicine for health care and treatment of diseases.23 Saudi Arabia 
has biodiversity, which consists of an admixture of elements from a variety regions like 
Asia, Africa and the Mediterranean. The mountainous area of southwestern Saudi Arabia 
is characterized by the richness of its flora and its species diversity.24 This region, from 
Taif to the Yemen border, contains about 70% of Saudi flora. The southwestern part of 
Saudi Arabia has the largest number of these medicinal plants spread in area named 
Alsawdah mountain near the city of Abha, the capital of Asir province.4 The climate in 
this region differs from all other regions of Saudi Arabia due to the heavy rainfall and 
high altitude.4 The climate around the Abha area is characterized by differences in 
temperature and relatively high rainfall throughout the year coupled with complex 
topography, resulting in the construction of unique and diverse plant communities.21  
Saudi flora contains 2,250 species arranged in 142 families; among these, more 
than 1,200 species are expected to have medicinal uses.25 However, a limited number of 
these plant species in this rich flora area have been screened for medicinal properties. 
1.3 Vitaceae family  
Plants of the grape family, the Vitaceae family, are identified by their climbing 
vines and tendrils and the distinctive clusters of berries.26 The leaves are represented 
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alternate, forming opposite from the tendrils and flowers. Flowers are regular with 4 or 5 
small sepals.27 There are 4 or 5 petals, which may be united at the tips, falling away as 
the flower opens with4 or 5 stamens. The ovary is positioned superior and consists of 2 
(rarely 3 to 6) united carpels (syncarpous) with the partition walls present to form an 
equal number of chambers.26, 27 It matures as a berry with 1 to 2 seeds per cell. Most 
members of the Grape family have edible leaves, stems, sap, and berries. The vegetation 
is often mildly astringent.27   
1.3.1 Genus  
The Cissus genus contains about 350 species; some of these species are used in 
herbal medicine as treatment or supplement for different ailments. For example, Bush 
Medicine Practitioners in Australia use C. hypoglauca as medicine for sore throat.28 In 
Asia, many cultures use local species of Cissus to treat different aliments. In China, C. 
assamica, is often used as an anti-snake venom as a result of decreasing endothelin-1 and 
sarafotoxin 6B,29 while in India and Sir Lanka, a species called Cissus quadrangularis is 
used for wound healing30 and as agent with anti-obesity activity.31 C. hamaderohensis is 
used in West Asia, it is reported to inhibit the angiotensin converting enzyme (ACE), 
aminopeptidase N (APN) and neutral endopeptidase (NGP).32 In Africa, several countries 
use species of Cissus in their herbal medicine; for example, in Cameroon, they use C. 
aralioides as an antimicrobial agent.33 Cissus rotundifolia is one of the known species in 
Africa and Asia. It shows anti-bacterial properties as a crude methanolic extract; 
however, it has not been investigated to identify the active constituent compounds. The 
methanolic extracts of cissus rotundifolia were screened for their antibacterial activity 
against different kind of bacteria such as against Bacillus cereus, Staphylococcus aureus, 
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Listeria monocytogenes, Escherichia coli.34,35 C. rotundifolia is one of the common plant 
species growing in southwestern Saudi Arabia and is used locally to treat different 
aliments in traditional medicine such as skin disease , burns and to control the high blood 
glucose in diabetic patient. Based on the efficiency of cissus rotundifolia in traditionally 
uses, Investigation of the antidiabetic activity of C. rotundifolia might lead to a new 
effective and safe antidiabetic agent so I focused this study on C. rotundifolia to 
determine the plant compounds that have potential antidiabetic activity. 
 
1.3.2 Cissus rotundifolia  
Cissus rotundifolia is a perennial, climber, evergreen wild plant belonging to the 
family of Vitaceae (grape family).36 It is known as a common Arabian wax cissus, Peru-
vian Grape Ivy, Venezuelan tree bine and, locally (in south of Saudi Arabia), as 
Algalaf.37 It is commonly used as a food thickener. Moreover, it was found to have many 
therapeutic effects such as hypoglycemic and hypolipidemic as an extract however it has 
not been investigated for specific active compound.34, 38 In addition, its extract shows 
antibacterial activity.35 Cissus rotundifolia grows extensively in the southern part of 
Saudi Arabia, and its leaves are widely consumed after cooking as leafy vegetables. It is 
commonly used to prepare various dishes according to the traditional dietary culture of 
locals and used as alternative medicine to reduce the blood glucose for diabetic patients 
and skin burns.37 However, it has not been studied for its antidiabetic activity. Therefore, 
this study aimed to evaluate the antidiabetic components of Cissus rotundifolia leaves. 
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1.3.3 Morphology  
 
Figure 1-3 : Cissus rotundifolia (Arabian wax cissus, grape ivy) 
 
The Cissu rotundifolia plant is a strong climber up to 30 ft long. Stems are often 
4-5 feet sloping and soft of hairless.27 Tendrils are 2-fid. C. Rotundifolia leaves are 
simple and sometimes lobed. Leaf-stalks are soft, up to 1 cm long and up to 8 x 8 cm in a 
circular to ovate shape, blunt at the tip, heart-shaped at the base with a toothed margin, 
velvety to hairless on both sides, thick and fleshy.27 Stipules are up to 4 mm long, 
semicircular, and hairless. The flowers are borne in lax cymes, leaf-alternated and at 
branch ends.36 Cymes are carried on 3 cm long stalks and flower-stalks are 4-5 mm and 
flower-buds are 3.5 x 1.5 mm.36 Petals are green and the ovary hairless with a length of 
0.5 mm. Fruit is 1.5 x 1.3 cm and red when ripe. Seeds are 1-2 per fruit, 9 mm. long, and 




The generic name originated from the Greek word kissos, meaning "ivy."39 In the 
1980s, the genus was divided according to certain details of the flower. The large 
caudiciform species were changed to the new genus Cyphostemma. The genus name was 
started by Car Linnaeus who used species epithets that are adjectives with the feminine 
grammatical gender in Latin (e.g., C. trifoliata L.). This matches the form of tree names 
ending in -us in Latin and having feminine gender.40 The Cissus rotundifolia plant 
belongs to one of the biggest kingdoms of plant called Plantae. The general taxonomy of 
Cissu rotundifolia as shown in table 1. 
 
Kingdom Plantae– plantes, Planta, Vegetal, plants 
Subkingdom Viridiplantae – green plants 
Infrakingdom Streptophyta – land plants 
Super division  Embryophyta 
Division Tracheophyta – vascular plants, tracheophytes 
Subdivision Spermatophytina – spermatophytes, seed plants, phanérogames 
Class  Magnoliopsida 
Superorder Rosanae 
Order Vitales 
Family Vitaceae – grapes 
Genus  Cissus L. – treebind, treebine 
Species Cissus rotundifolia (Forssk.) Vahl – Venezuelan treebine 
Table 1-1: General taxonomy of Cissu rotundifolia. 
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The species of Cissus genus are frequently used as medicinal plants as they 
contain vitamins, proteins, polyphenols and carbohydrates. Leaves of Cissus genus 
contain Sterols, Quinones, and Phenolic compounds. In addition to, Anthocyanins, 
Saponins and flavonoids are found in the plants leaves and fruits.41 Phytochemical studies 
on methanol extract has been reported the presence of triterpenes including α- and β- 
amyrins, β-sitosterol, ketosteroids, phenols, tannins, carotene and vitamin C. 41 
1.3.5 Occurrences of Cissus rotundifolia 
Cissus rotundifolia is one of the most common plants that grow freely in the wild 
with no agricultural treatments that allow this plant to be consumed as a food.37 This 
species of plant is consumed worldwide in both developing and developed nations and 
provides nutrition and food security for poor rural communities in several regions.42, 43 
For example, C. rotundifolia serves  as a diet supplement in Japan, Europe and North 
American.44-46 The known plants of these species are rich in minerals, dietary fiber, 
vitamins, amino acids and fatty acids.47, 48 Previous studies showed that the 
corresponding domesticated types of these plants have some therapeutic potential; for 
example, phytic acid has been shown to have anticancer and antioxidant activity.49, 50 
Therefore, there are indeed reasons to investigate the nutritional impacts of this plant. 
Moreover, it is necessary to understand its impacts on consumer’s health51. 
1.3.6 Medical uses of Cissus Rotundifolia 
Cissus rotundifolia (fam, Vitaceae) spread from the African Mediterranean region 
and are currently cultivated in many countries worldwide.37 It was consumed by the 
ancient Greeks, Romans and Persians and reached the Far East being used either as a 
food or alternative medicinal as anti-inflammatory.26 In the southwestern part of Saudi 
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Arabia, people use the leaves of cissus rotundifolia to control a variety of medical issues 
like skin disease, burns, cold symptoms and, in traditional medicine for the patient who 
suffers from diabetes to control the high level of glucose in the blood.37 
1.4 Diabetes mellitus overview 
Diabetes mellitus (DM) is a metabolic disease characterized by high levels of blood 
glucose resulting from defects in insulin production or insulin action. The increase of the 
diabetes rate world-wide is projected to reach pandemic levels over the next 10-20 years. 
1.5  Classification of diabetes mellitus 
In 1997, the American Diabetes Association (ADA) established new classification 
criteria for diabetes mellitus disease.52 The ADA classified Diabetes in four clinical 
classes: the first clinical class of diabetes is Type 1 diabetes (T1DM) based on β-cell 
destruction leading to absolute insulin deficiency. The second class is the most common 
type of diabetes; type 2 diabetes mellitus (T2DM) diagnosed due to a progressive insulin 
secretory weakness on the background of insulin resistance. The third clinical class of 
diabetes includes other specific types of diabetes resulting from other causes such as 
genetic defects in insulin action, genetic defects in β-cell function and diseases of the 
exocrine pancreas. The fourth class is Gestational diabetes mellitus (GDM) that occurs 
under specific health conditions and is diagnosed during pregnancy.53 
1.6 Clinical diagnosis of diabetes  
Diabetes can be diagnosed through direct blood glucose level testing during 
individuals primary clinical care with low-risk and diabetes risk assessment. Early 
diagnosis of type 2 diabetes mellitus (T2DM) is recognized by blood tests that measure 
plasma glucose levels (PG).52 The fasting plasma glucose level (FPG) is the most 
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preferred test to detect the blood glucose level in the body with a level of ≥126 mg/dL or 
7.0 mmol/L verified by doing the test again on another clinic visit. This test needs fasting 
for at least 8 h. Another test is the 2-hour plasma glucose (PG) of ≥200 mg/dL or 
11.1 mmol/L in a patient with frank symptoms of diabetes like polyuria, unexplained 
weight loss and polydipsia.54 A positive result of the oral glucose tolerance test (OGTT) 
will demonstrate a PG level of ≥200 mg/dL or 11.1 mmol/L after a glucose load 
containing 75 g of glucose solution in water. Although the two-hour PG OGTT test is 
more accurate, it is not commonly used in the clinic because of less convenience and 
more expense for patients.  
1.7 Clinical management of diabetes 
 The initial evaluation required for a patient suffering from a high blood glucose 
level is specific to the patient’s risk factors and symptoms. Comprehensive care for a 
patient to help to optimally manage the diabetic case or even diagnose prediabetes is 
necessary. The main way to control diabetes proceeds from Non-pharmacological therapy 
(e.g. lifestyle change) to using antidiabetic therapy followed by blood glucose 
monitoring. 
1.7.1 Non-pharmacological Management 
1.7.1.1 Lifestyle Modification 
Lifestyle modification is the most effective way to prevent one of the most 
common type of diabetes (T2D) and leads to about a 58% reduction in risks over 3 years 
.55 The patient suffering from one or two of high risk factors is highly recommended to 
implement lifestyle changes such as healthy diet and more time exercising. Later, the 
diabetic patient already suffering from diabetes, needs to follow up with nutrition 
 18 
specialists to follow the right diet that will help to avoid sugar sources that increase the 
level of blood glucose. On the other hand, the patient diagnosed with diabetes needs to 
moderate his/her weight loss (~ 7% of body weight) as one of the important tactics to 
control diabetes and impact the cholesterol level in addition to positively controlling  
blood pressure.55 Diabetic patient can manage weight loss with a balanced diet, avoiding 
carbohydrates and control of the calories daily consumed.56, 57 
 Also, other studies show that exercise plays an important role in preventing and 
controlling hyperglycemia (lower HbA1C level by 0.66%).57 Exercise is considered an 
essential part in order to prevent and control both prediabetes and diabetes. The U.S. 
Department of Health and Human Services recommends that adults ≥18 years of age need 
to do at least 150 min/week of moderate exercise, such as walking for 15 to 20 min, or 75 
min/week of intensity physical activity like running and aerobics over at least 3 days per 
week to achieve the benefits.52, 54 For patients younger than 18 years old, the U.S. 
Department of Health and Human services recommends 60 min of physical activity 
daily.52 
 In addition to the lifestyle modifications mentioned previously, the diabetes 
patient needs to moderate alcohol consumption, especially the patient suffering from any 
another cardiovascular disease, such as hypertension, with diabetes. Also, consumption of 
alcohol in a fasted state is considered life-threatening in that it can cause hypoglycemia 
and coma. In general, diabetic patients need counseling and psychosocial support to 
successfully fight the complication effects of diabetes.58 
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1.7.2 Pharmacological Management 
Diabetes mellitus is a chronic disease difficult to control but the management of 
this disease emphasizes keeping the plasma glucose levels in the blood as close as 
possible to a normal range with the support of glucose lowering medications, healthy 
nutrition and exercise.52 Target goals depend on each patient and the optimal way to 
control the diabetes is determined after consultation with a medical practitioner. The 
treatment goal differs from young, adult and elderly to reach normoglycemia without 
significant hypoglycemia. Hemoglobin A1c (HbA1c) is the shape of hemoglobin (a 
blood pigment that carries oxygen) that binds to glucose. The HbA1c test is used to 
screen patient glycaemia and the key element is patient education and understanding of 
the disease and complications related to diabetes, such as cardiovascular disease. 
Management of diabetes depends on the type of diabetes. In general, Type 1 diabetes 
mellitus is produced by absence of insulin; therefore, insulin should be controlled in a 
patient suffering with Type 1 diabetes. Type 2 diabetes is described by insulin resistance 
and treatments include oral anti-diabetic medications.59, 60  
1.7.2.1 Insulin Therapy 
Insulin is used for treatment of diabetes mellitus Type 1 and includes management 
of combined split-mixed injections. Moreover, insulin is used in acute diabetes 
emergencies, for example diabetic ketoacidosis (DKA) and pregnancy. Also, insulin can 
be used as a supplement in diabetes Type 2 in case oral therapy fails to control blood 
glucose concentrations. The main adverse effect observed with insulin therapy is 
hypoglycemia, which might lead to brain damage. Mostly, patients with chronic renal 
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impairment needed less insulin, so regular control of blood glucose levels must be made 
to minimize the risk of hypoglycemia.61  
1.7.2.2 Oral antidiabetic 
There are major classes of oral antidiabetic medications, including biguanides, 
sulfonylureas, meglitinide, thiazolidinedione (TZD), dipeptidyl peptidase 4 (DPP-4) 
inhibitors and α-glucosidase inhibitors. Diabetes diagnosis depends on the HbA1C test 
result, if HbA1C  level rises to 7.5% while on medication or if the initial HbA1C is ≥9%, 
combination therapy with two oral agents, or with insulin, may be considered.61, 62 
However, these medications have limitations regarding efficiency, side effects and patient 
compliance.61  
1.7.2.2.1 Biguanide  
Biguanide and its derivatives are the most common and available treatment for 
diabetes. The discovery of biguanide started from extraction of a plant called Galega 
officinalis; this plant was found to have different components, such as guanidine, 
galegine and biguanide, which showed potential antidiabetic activity through decreasing 
blood glucose levels.63 Metformin is the most common, cheapest available and the first-
line oral medicine for type 2 diabetes mellitus (T2DM). Metformin is a biguanide that 
activates adenosine monophosphate-activated protein kinase in the liver, causing hepatic 
uptake of glucose and inhibiting gluconeogenesis through complex effects on the 
mitochondrial enzymes.63 Metformin is a small molecule synthesized based on the 
pharmacophore of the natural product compound isolated called galegine from Galega 
officinalis. Metformin is the first line drug of T2DM, and it reduces the risk of 
complications and mortality rates in patients through decreasing hepatic glucose synthesis 
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(gluconeogenesis) and sensitizing peripheral tissues to insulin.63 However, metformin has 
side effects: a risk of hypoglycemia and low chances of weight gain. Metformin might 
also cause vitamin B12 and folic acid deficiency.64 This needs to be monitored, especially 
in elderly patients. Another potential problem resulting from the use of metformin is a 
decrease in the drug’s efficiency as diabetes progresses. Metformin is highly effective 
when there is enough insulin production; however, when diabetes reaches the state of 
breakdown of β-cells and results in a type 1 phenotype, metformin loses its efficacy.61 
1.7.2.2.2 Sulphonylureas  
Sulphonylureas is a class of organic compounds used as oral antihyperglycemic 
drugs. The mechanism of action of sulphonylurease occurs through binding to the 
sulfonylurea receptor on the beta cell surface to indicate secretion of insulin from the 
pancreatic beta cells. Sulphonylureas are classified into two main groups: first generation 
and second generation. Second generation sulphonylureas are characterized by fewer side 
effects and more effective action than the first generation. The duration of action is 
shorter in the first generation compared to the second generation. Universally used first 
generation drugs are tolazamide, acetohexamide, tolbutamide and chlorpropamide. 
Examples of the most commonly used second generation drugs are glibenclamide, 
glipizide, glimepiride and gliclazide. Sulphonylurease is used either as monotherapy or in 
combination with other antihyperglycemic drugs. The major side effects of this class of 
antidiabetic drugs are hypoglycemia and weight gain.54, 65  
1.7.2.2.3 Thiazolidinediones (TZDs)  
Thiazolidinediones (TZDs) are a class of antidiabetic drugs use by patients 
suffering from type 2 diabetes (T2DM). Rosiglitazone and Pioglitazone are the most 
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common TDZ drugs currently available. The mechanism of action of TDZs depends on 
binding to the peroxisome proliferator activated receptor gamma (PPAR-γ), a kind of 
nuclear regulatory protein located in fat, muscle and liver. TZDs are expected to increase 
insulin sensitivity, decrease cellular resistance and improve glycaemic control based on 
enough production of insulin by pancreatic beta cells. TZDs might be used either as 
monotherapy or in arrangement with other oral antidiabetic medications. In fact, use of 
this class of drugs (TZDs) has been reduced due to side effects, such as myocardial 
infarction, angina fluid retention, heart failure, hypoglycemia and liver injury as indicated 
by multiple retrospective studies.65, 66  
1.7.2.2.4 α-glucosidase inhibitors 
Alpha glucosidase inhibitors (AGIs) are one of the first line therapy classes of anti-
diabetic drugs. These oral antidiabetic medicines are enzyme inhibitors that do not affect 
the pancreas during the mechanism of action. The mechanism of action of AGIs depends 
on the delay of carbohydrate absorption in the gastrointestinal tract. In addition, AGIs 
control postprandial hyperglycemia and provide cardiovascular benefit. Carbohydrates 
are present as oligo — or poly — saccharides. Polysaccharides need to be broken down 
to monosaccharides (glucose, fructose, galactose) for digestion. For example, starch is 
one of the most common polysaccharides digested through the alpha glucosidase enzyme 
that breaks starch (polysaccharides) down to monosaccharides. Acarbose inhibits alpha-
glucosidase enzyme, thus preventing absorption of starch from the brush border of the 
intestine. Therefore, AGIs class of antidiabetic medicine, which delays intestinal 
carbohydrate absorption, reduces postprandial glycaemia and helps manage diabetes.67  
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1.8 Diabetic case statistics in Saudi Arabia  
425 million people suffer from diabetes worldwide according to the World Health 
Organization and more than 39 million people in the MENA region. Saudi Arabia is one 
of the MENA region countries that has a high prevalence rate of diabetes disease. By 
2045, the expected number of diabetic patients around the world will rise to 67 million. 
There were 3.852.000 people suffering from diabetes in Saudi Arabia in 2017 while the 
total adult population is about 20,770,000 people, so the prevalence of diabetes in adults 
is approximately 18.5%.61 
In Saudi Arabia, diabetic disease occurs as one of the major medical issues and 
cardiovascular disease is considered the first leading cause of death. Saudi Arabia has the 
highest prevalence rates of diabetics with the increase of diabetes cases in Saudi Arabia 
affecting more than one fourth of the adult Saudi population.68 The dramatic increase in 
the prevalence rate of diabetes  is a result of rapid socioeconomic development, lifestyle 
changes and a change in dietary patterns. Etiological factors that cause high blood glucose 
level like obesity, dietary habits and lack of exercise also contribute.69  
1.9 Cissus rotundifolia as potential therapy for different medical issues 
Cissus Rotundifolia as a crude extract has been reported to possess biological 
activities.70, 71 72  This section provides a summary of the potential antimalarial and 
antidiabetic effects of cissus rotundifolia as an extract. 
1.9.1 Antimalarial activity of cissus rotundifolia as a crude extract  
Malaria is an infectious disease that remains associated with considerable 
morbidity and mortality and economic impact on developing societies.70 According to the 
World Health Organization (WHO), malaria is widespread in 91 countries, mostly in 
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Africa, Asia and Latin America. Approximately 40% of the world’s population is at risk 
and it will continue to be distributed widely, essentially due to the drug resistance 
developed by Plasmodium falciparum.72 A study of medicinal plant assessment showed 
the antimalarial activity of crude extracts of Cissus rotundifolia.70 The results confirm 
that this plant, consumed in traditional medicine, has significant antimalaria activity in 
vitro and verified its use in traditional medicine.72, 73 However, in vivo studies of this 
medicinal plant need to be completed to determine toxicity of the active constituents, 
pharmacokinetic properties and diffusion in different body sites in addition to side 
effects.73   
1.9.2 Antidiabetic activity of cissus rotundifolia as a crude extract 
Cissus rotundifolia is a climbing or prostrate shrub found throughout Africa and the 
Arabian Peninsula being used as food. C. rotundifolia leaves extract has shown anti-
diabetic as well as antiparasitic properties.34, 74 In Saudi Arabia, the boiled leaves of C. 
rotundifolia are prepared with meals as an appetizer and also used as an antipyretic in the 
treatment of malaria and dengue fever.71 The present study was designed to evaluate the 
hypoglycemic activity of C. rotundifolia components using different pathways to control 
glucose blood levels compared to the most common antidiabetic drugs like acarbose and 
metformin. 
1.10 Molecular target of diabetes mellitus  
Diabetes mellitus known as high level of glucose in the blood. The two main 
sources of glucose in the body comes from either degradation of complex carbohydrates 
or the producing of the glucose by liver as result of gluconeogenesis process. In order to 
control of blood glucose level in early stage need to delay the absorption of glucose to the 
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blood through inhibition Alpha-glucosidase enzyme as a molecular target that used to 
breakdown the carbohydrate consumed to glucose. Moreover, through reduce the 
production of glucose in the body that result from gluconeogenesis process. 
 
1.10.1 Alpha-glucosidase (AG) enzyme  
Alpha-glucosidase enzyme is located in the brush border in the small intestine, 
which is the key enzyme in carbohydrate synthesis and breakdown.75 Alpha-glucosidase  
is an exo-type carbohydrase, breaking glycosidic bonds in complex polysaccharides to 
release absorbable monosaccharides (Fig. 1-4).76 The degradation of dietary 
carbohydrates is considered the principal source of increased levels of glucose in the 
blood. After hydrolysis of the complex dietary carbohydrate, the consequent absorption 
in the intestine is made by alpha-glucosidases.77 One of the main strategies to control 
type 2 Diabetes mellitus (T2D) is to decrease postprandial high blood glucose levels by 
delaying the absorption of glucose through inhibition of carbohydrate-hydrolyzing 
enzymes, alpha-glucosidase, in the digestive processes.78 Furthermore, one interesting 
property of the alpha-glucosidase inhibitor is its ability to both improve and extend 
glucagon-like peptide 1 (GLP-1) secretion in normal individuals and patients with Type 2 
diabetes mellitus disease.79, 80 
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Figure 1-4: Mechanism of action for alpha-glucosidase enzyme.81 
1.10.2 Gluconeogenesis Inhibition   
Gluconeogenesis is the main pathway to produce glucose in human body. In 
diabetic patients, gluconeogenesis is high so the current target to control diabetic disease 
is to inhibit gluconeogenesis in order to manage hyperglycemia. Gluconeogenesis is the 
reversal of glycolysis, with some workarounds for the irreversible reactions in this 
pathway.82 The reactions that interact for glycolysis and gluconeogenesis are presented in 
blue in the figure 2-1, whereas gluconeogenesis’s reactions are shown in red.83 It is 
realized that both pyruvate and oxaloacetate as substrates from the citric acid cycle are 
starting points for gluconeogenesis. These pathways are presented here by green arrows. 
The major substrate source for gluconeogenesis is protein, both dietary and endogenous. 
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Moreover, any of the TCA cycle intermediates can serve as substrates for 
gluconeogenesis. 
Gluconeogenesis occurs only in the liver and the kidneys, and the liver is 
synthesizing most of the glucose. Gluconeogenesis provides stable blood glucose levels 
between meals; however, it is found to be high in diabetic patients. Gluconeogenesis also 
helps us to maintain glucose levels when on a diet that is low in carbohydrates.83 
Therefore, based on the similarity in the chemical structure between the isolated 
compound from cissus rotundifolia and citric acid cycle substrates, our hypothesis builds 
on the investigation of the binding affinity of isolated compound and citric acid cycle 





Figure 1-5: Gluconeogenesis process (in red) starts by oxaloacetate substrate from citric acid 
cycle reactions. 
 
The citric acid cycle, or tricarboxylic acid cycle, has a fundamental role in the 
gluconeogenesis process that is considered the main pathway of the hepatic production of 
glucose. The citric acid cycle is a series of reactions in mitochondria that result from 
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oxidization of the acetyl moiety of acetyl-CoA to CO2 and decreases coenzymes that are 
reoxidized through the electron transport chain related to the formation of ATP. The 
enzymes involving in citric acid cycle play important role in regulation of 
gluconeogenesis through catalyzes each step of the cycle to form the substrates. 
Oxaloacetate is a substrate of citric acid cycle and it is the starting material for 
gluconeogenesis. Although the properties of citric acid cycle enzymes have been studied, 
the reports of targeted small molecule modulators of the activity have been limited. 
Therefore, in this study the isolated compound and small analogs investigated for their 
binding affinity to citric acid cycle enzymes that might lead to inhibition activity of 
gluconeogenesis. 
 
1.11 Project objectives 
1. Extraction, isolation, and structural elucidation of the active constituents 
from Cissus Rotundifolia with potential anti-diabetic activity using bioassay-
guided fractionation. 
Cissus Rotundifolia (Vitaceae), which is locally called Algalaf, is 
commonly used in Saudi folk medicine to control high blood glucose level 
(Diabetes Mellitus). The overall objective of this study was the extraction, 
isolation and structural elucidation of the active constituents with potential 
antidiabetic activity from Cissus Rotundifolia using bioassay-guided fractionation. 
The antidiabetic activities of the extracts, fractions and pure isolated compounds 
obtained from the bioassay-guided fractionation were evaluated in vitro using 
alpha glucosidase enzyme inhibition bioassay and glucose uptake induction to the 
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cell using liver cell line (HepG2). The chemical structures of the pure isolated 
compounds were elucidated using H NMR, C15 NMR and 2D NMR. To the best 
of our knowledge, this is the first chemical profile investigation of the antidiabetic 
activities in Cissus Rotundifolia. 
2.  In-vitro evaluation of anti-diabetic activity of isolated compounds. 
One of the current targets of novel antidiabetic agents to control high 
blood glucose in the blood is glucose uptake induction. In fact, the most important 
effects of insulin on glucose metabolism are the regulation of GLUT4 trafficking 
and, consequently, glucose uptake.84 Moreover, glucose transport plays the 
essential role in insulin-regulated glucose metabolism. The isolated compounds 
with potential antidiabetic activity from cissus rotundifolia extract conduct an in 
vitro evaluation of glucose uptake induction through glucose uptake assay.  
3.  In-silico molecular modeling study of isolated compounds targeting citric 
acid cycle enzymes. 
Gluconeogenesis provides stable blood glucose levels between meals; 
however, it is found high in diabetic patients. Gluconeogenesis also helps us to 
maintain appropriate glucose levels when on a diet low in carbohydrates. 
Therefore, based on the similarity in the chemical structure between the isolated 
compound from cissus rotundifolia and citric acid cycle substrates, our hypothesis 
builds on investigations of the binding affinity of the isolated compound and citric 
acid cycle enzymes in order to screen the inhibition activity for gluconeogenesis 
to control the hyperglycemia. Gluconeogenesis steps start by oxaloacetate, which 
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is one of the citric acid cycle substrates. Therefore, gluconeogenesis could be 
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2 CHAPTER TWO: ISOLATION OF ANTIDIABETIC CONSTITUENTS 




 Nature has long been the source of the basic elements of life such as food, medicine, 
clothing and shelter.1 Natural products performed a significant role in human disease 
therapy and compounds derived from natural products have continuously been noted as a 
valued sources for drug discovery.1, 2 
Plants are the richest source of remedies and the use of some plants is known in 
herbal medicine throughout human history.3-5 The current predicted number of plant 
species worldwide is around 250,000 species.6, 7  However, a limited number of these 
plant species have been screened for medicinal properties. In fact, less than 10% of 
medicinal plants species have been investigated and validated for their medical 
activities.6 Plants have always been a very rich source for drug discovery, and the 
majority of currently available drugs on the market have been derived directly or 
indirectly from plants.6, 8 For example, several available drugs derived from plants for 
different diseases therapy exist, such as  the anticancer drug vincristine from Vinca rosea, 
the narcotic analgesic morphine from Papaver somniferum, the antimalarial drug 
artemisinin from Artemisia annua, the anticancer drug Taxol from Taxus brevifolia, the 
antibiotic penicillin from Penicillium ssp 1 and the most common antidiabetic available 
drug, Metformin, derived from Galega officinalis.9 10 
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The Vitaceae is a commonly known plant family that forms one of the largest and 
most diverse plant families worldwide, growing in a variety of environments. This family 
contains more than 900 known species, occurs in 14 genera, and is mainly spread in 
tropical and subtropical areas of the world.11 The largest genus of this family 
is Cissus, including about 350 species. Some of the important genera belonging to the 
Vitaceae family include Acareosperma, Ampelocissu, Cyphostemma, Amplopsis, Psedra, 
Leea, Vitis and Cissus.4 Most of the plants in this family are identified by their climbing 
vines, tendrils and distinctive clusters of berries. Their leaves are alternate, forming 
opposite from the tendrils and flowers. Flowers are regular with 4 or 5 small sepals.12 
Vitaceae is also considered one of the most economically important plant families due to 
the cultivation of many edible Vitaceae species, including the European wine grape (V. 
vinifera) and the North American fox grape (V. labrusca) which are the parent species of 
most of the cultivated slipskin American grapes. The Boston ivy (q.v.; Parthenocissus 
tricuspidata) and the Virginia creeper (q.v.; P. quinquefolia) are the most common 
woody vines in the eastern United States.4, 13 The Vitaceae family has drawn the attention 
of many researchers since their fruits, leaves and vegetables are traditionally consumed as 
food and medicine to treat some skin burns in addition to uses as a diet supplement to 
reduce the blood glucose level in diabetic patients  .14 A number of plant species from the 
Vitaceae family have been extensively reviewed in the literature for their medicinal 
properties, such as Cissus quadrangularis, C. araloides, C. assamica, C. 
hamaderohensis, C. hypoglauca, C. sicyoides, C. debilis, C. ibuensis, C. populne, C. 
verticillata and C. rotundifolia  screened as a crude extracts and showed that they have 
medicinal activity as anti-inflammatory and anti-malaria, in addition to hypoglycemic 
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activity as a methanolic extract however, it is not significantly investigate for the active 
constituents compounds.11 Several parts of the plants, including the seeds, fruits and 
leaves, of the Vitaceae family have been consumed by humans and reported to have 
medicinal properties.11, 15  
Cissus rotundifolia is a perennial, climber, evergreen, wild plant belonging to the 
family of Vitaceae (grape family). It is known as a common Arabian wax cissus, 
Peruvian Grape Ivy, Venezuelan tree bine and locally (in the south of Saudi Arabia) as 
Algalaf. It is commonly used as a food thickener. Moreover, it was found to have many 
therapeutic effects as a hypoglycemic and hypolipidemic , based on the literature study, 
the hypoglycemic activities of plant extracts of C. rotundifolia still not fully investigated 
to specific mechanism of action however the study mentioned that the antidiabetic 
activity of C. rotundifolia extract could be due to the stimulation of insulin secretion from 
the remaining β-cells which promotes tissue glucose utilization in diabetic rats either by 
enhancing its uptake and metabolism or by inhibiting hepatic gluconeogenesis. Moreover, 
C. rotundifolia extracts significantly corrected the levels of cholesterol and triglycerides 
towards normal.  This improvement may be partly attributed to the increase in insulin 
secretion that affects lipid metabolism and to the regeneration of β-cell as a result of the 
decrease in production of free radicals by lipid peroxidation.16 In addition, the methanolic 
extract of cissus rotundifolia has been reported to possess antibacterial activity when 
tested against E. coli, S. infantis, S. aureus and L. monocytogenes in study where only the 
extracts of edible plants were screened for their antibacterial activity however the 
investigation of specific active compound need future studies.17 
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 .18 Cissus rotundifolia grows extensively in the southern part of Saudi Arabia, and its 
leaves are widely consumed after cooking as leafy vegetables. Cissus rotundifolia extract 
has been reported to contain components such as flavonoid, hydrolysable tannin and 
vitamin C. In addition to, an appreciable amount of protein, fat, crude fiber and minerals. 
According to nutritional evaluation of cissus rotundifolia, the protein fraction includes a 
relatively high level of essential amino acids; fat contains a high concentration of 
unsaturated fatty acids; Macro elements (Magnesium, Sodium, Potassium; Microelements 
(Iron, Zinc, Manganese, Copper and Chromium). However, up to present, no 
phytochemical studies have been reported regarding the isolation and identification of the 
phytoconstituents of C. rotundifolia. It is commonly prepared in various dishes according 
to the traditional dietary culture of locals and is also used as an alternative medicine. 
However, it has not been studied for its antidiabetic activity. Therefore, this study aims to 
evaluate the antidiabetic components of Cissus rotundifolia leaves. 
2.2 Distribution and uses of cissus rotundifolia plant in Saudi Arabia 
 
Saudi Arabia is one of the Middle East countries with a population of more than 
25 million people. In Saudi Arabia, people live in both urban and rural areas and sectors 
still use traditional, natural medicine for health care and treatment of diseases.19 Saudi 
Arabia has plant biodiversity, which consists of an admixture of elements from variety 
regions like Asia, Africa, and the Mediterranean. The mountainous area of southwestern 
Saudi Arabia is characterized by the richness of its flora and species diversity.20  Cissus 
rotundifolia is a perennial, climber, evergreen wild plant belonging to the family of 
Vitaceae (grape family).21 It is known as a common Arabian wax cissus, Peru-vian Grape 
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Ivy, Venezuelan tree bine and, locally (in south of Saudi Arabia), as Algalaf.22 It is 
commonly used as a food thickener. Cissus rotundifolia grows extensively in the 
southern part of Saudi Arabia, and its leaves are widely consumed after cooking as leafy 
vegetables. It is commonly used to prepare various dishes according to the traditional 
dietary culture of locals and used as alternative medicine to treat some skin burns and 
also uses to reduce the blood glucose for diabetic patients. However, it has not been 
investigated for its antidiabetic activity. Therefore, this study aimed to evaluate the 
antidiabetic components of Cissus rotundifolia leaves using the bioassay guided 
separation of methanolic extract of C. rotundifolia leaves.  
 
 
2.3 Aim of the study  
Identification of  the chemical constituents of the plants used in traditional 
medicine is very important since several studies have found them to have potential 
biological activities, such as potential antidiabetic activity.23 All established information 
will expand our current knowledge of the ethnopharmacology of the plants that have 
medicinal properties and are used in traditional medicine and might aid in identifying 
new chemical entities with antidiabetic activities.23 The aim of the present study was the 
extraction, isolation and structural elucidation of the active constituents with potential 
anti-diabetic activity from Cissus rotundifolia using bioassay-guided fractionation. Cissus 
rotundifolia (Figure 2-13) (Vitaceae), which is locally called Algalaf, is used in Saudi 
traditional medicine for the treatment of skin burn, malaria and control of diabetes 
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2.4 Molecular target of diabetes mellitus 
Diabetes mellitus known as high level of glucose in the blood. The two main 
sources of glucose in the body comes from either degradation of complex carbohydrates 
or the producing of the glucose by liver as result of gluconeogenesis process. In order to 
control of blood glucose level in early stage need to delay the absorption of glucose to the 
blood through inhibition Alpha-glucosidase enzyme which play an important role on 
regulation of blood glucose level in the blood. 
 
2.4.1 Alpha-glucosidase (AG) enzyme  
 
Alpha-glucosidase is a carbohydrase enzyme, breaking glycosidic bonds in 
complex polysaccharides to release absorbable monosaccharides (fig. 2-1).24 The 
degradation of dietary carbohydrates is considered the principal source of increased 
glucose in the blood. After the hydrolysis of the complex dietary carbohydrate, the 
consequent absorption in the intestine is made by alpha-glucosidases.25 One of the main 
strategies to control type 2 Diabetes mellitus (T2D) is to decrease postprandial high blood 
glucose level by delaying the absorption of glucose through inhibition of carbohydrate-




























2.5 Materials and methods 
2.5.1 General procedures and reagents 
1H-NMR, 13C-NMR and 2D-NMR were conducted using Bruker AVANCE-400 
MHz and 600 MHz NMR spectrometer in deuterated chloroform (CDCl3) using 
tetramethylsilane (TMS) as the internal standard; chemical shifts are given in ä (ppm) 
values. Column chromatography was carried out using silica gel (230–400 mesh) 
purchased from Sorbent Technologies (Norcross, GA, USA). TLC was performed using 
pre-coated silica gel PE Sheets purchased from Sorbent Technologies (Norcross, GA, 
USA), visualized under ultraviolet at 254 nm, stained with Ceric Ammonium Molybdate 
(CAM) stain and followed by heating. All solvents were obtained from commercial 
suppliers and used as received. 
α-Glucosidase enzyme (Cat. No. G 5003, Sigma Aldrich Chemical Co, USA). 
Bovine serum albumin (Sigma Aldrich Chemical Co, USA), Sodium azide (Sigma 
Aldrich Chemical Co, USA). Para nitrophenyl-α-d-glucopyranoside (Cat No: N 1377, 
Sigma Aldrich Chemical Co, USA). Acarbose (Sigma Aldrich, PHR1253, USA). 
2.5.2 Plant materials 
Fresh leaves of Cissus rotundifolia were collected in June 2016 from the area near to 
Abha, Saudi Arabia. Al-Sawdah Mountain, the site of Cissus rotundifolia plant 
collection, is located east of Abha, in area between latitude 17°30’ north and 21°00’ north 
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and longitude 41°30’ east and 44°30’. The plant was botanically authenticated, and a 
voucher specimen was deposited in Pharmacognosy Department Herbarium, College of 
Pharmacy, King Khaled University, Abha, Saudi Arabia. 
2.5.3 Preparation of plant extracts and fractions 
The leaves of Cissus rotundifolia (7 kg) were cut into small pieces and 
homogenized in methanol (a blender was filled to third (1/3) volume with leaves, 1.5 L of 
methanol was added, the mixture was homogenized for 5 min). Then, the mixture was 
macerated in methanol for 72 hours. The methanol extract was filtered, concentrated 
under reduced pressure at 40°C using a rotary evaporator and lyophilized to afford a 
residue. The dried methanol extract (210 g) was dispersed in deionized water (500 ml) 
and partitioned sequentially with n-hexane (500 ml×3) and ethyl acetate (500 ml×3).The 
combined solvent of each partitioned extract was concentrated under reduced pressure at 
40°C using the rotary evaporator and freeze dried for 72 hours to yield an n-hexane 
fraction (32 g), an ethylacetate fraction (20 g) and the remainder of the water fraction 
(158 g). All fractions were tested for their antidiabetic activity through evaluation of their 
inhibition activity of α -glucosidase enzyme using α -glucosidase inhibition bioassay. 
 
2.5.4 Isolation 
According to the bioassay-guided fractionation, the ethyl acetate fraction showed 
the greatest potential antidiabetic activity, thus this fraction was selected for further 
study. The EtOAc fraction was subjected to column chromatography on silica gel (300 g) 
and eluted with stepwise gradients of n-hexane/EtOAc (100:0, 90:10, 80:20, 70:30, 
60:40, 50:50, 45:55, 40:60, 30:70, 20:80, 10:90, 0:100 v/v) and finally with 2 L methanol. 
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A total number of 532 fractions (20mL each) were collected and combined on the basis 
of their TLC profiles into five main fractions as follows: fraction I (70-136) (941 mg), 
Fraction II (136-237) (633 mg), Fraction III (238-298) (460g), Fraction IV (299-363) 
(302g) and Fraction V (362-534) (720 mg). All these sub-fractions are examined for α -
glucosidase inhibition bioassay in order to evaluate their antidiabetic activity through 
inhibition activity of α -glucosidase enzyme. 
2.5.5 Alpha-glucosidase inhibition assay 
α-Glucosidase inhibitors act as competitive inhibitors of intestinal α-glucosidase 
enzyme, which results in delay of the digestion and subsequent absorption of elevated 
blood glucose levels.27 The extracts were pre-incubated with the α-glucosidase enzyme 
before adding the substrate p-nitrophenyl- α-d-glucopyranoside (PNPG). The α-
glucosidase enzyme (Cat. No. G 5003, Sigma Aldrich Chemical Co, USA) was dissolved 
at a concentration of 0.1 U/ml in 100 mM phosphate buffer, pH 7.0, containing bovine 
serum albumin 2000 mg/ml (Sigma Aldrich Chemical Co, USA), and sodium azide 200 
mg/ml (Sigma Aldrich Chemical Co, USA), which was used as enzyme source. Para 
nitrophenyl-α-d-glucopyranoside (Cat No: N 1377, Sigma Aldrich Chemical Co, USA) 
was used as substrate. Cissus rotundifolia extract was weighed and serial dilutions of 50, 
25, and 12.50 mg/ml were made up with equal volumes of dimethylsulfoxide and 
distilled water. Ten microliters of C. rotundifolia extract dilutions were incubated for 5 
min with 50 µl of the α-glucosidase enzyme source. Then, 50 µl of substrate was added 
and incubated for 5 min at room temperature. The pre-substrate and post substrate 
addition absorbance was measured at 405 nm on a microplate reader (Biotek Instruments 
Inc, USA). Percent α-glucosidase inhibition was calculated as follows: (1–B/A) Å~ 100, 
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where (A) is the absorbance of control and, (B) is the absorbance of samples containing 
extracts. 
 The activity of the α-glucosidase enzyme was measured by determining the color 
developed by the release of p-nitrophenol resulting from the hydrolysis of substrate 
PNPG by α – glucosidase using a spectrophotometric method. Experiments were done in 
triplicate. Acarbose (Sigma Aldrich, PHR1253, USA) was dissolved in distilled water 
and serial dilutions of 10, 5 and 2.5 mg/ml were made and used as positive controls. 
2.6 Results and Discussion 
2.6.1 Isolation and structure elucidation 
The methanolic extract of the leaves of Cissus rotundifolia was dispersed in 
deionized water and partitioned sequentially with n-hexane and ethyl acetate. Based on 
the bioassay-guided fractionation, the ethyl acetate fraction showed the highest potential 
antidiabetic activities and thus it was subjected to a series of chromatography techniques 
to yield 6 compounds (Figure 2-12). 
Compound 1 was isolated as a white powder, then identified using 1H, 13C and 2D 
NMR spectra. 1H NMR spectrum showed signals mainly in the upfield region. The 
spectra showed only two signals with sharp chemical shifts values; the first one 
resonated in the olefinic region and the other was observed a little up field region. The 
1H-NMR spectra of compound 1 also exhibited a signal corresponding to the proton 
connected to C-3 hydroxyl group, which appeared as a multiplet at δ 3.46 (1H, m). Six 
other proton signals were marked, including four secondary methyl groups (δH 0.91, 
0.82, 0.81 and 0.79 all doublets with J = 6.6, 7.2, 6.4 and 6.4 Hz respectively) and two 
tertiary methyl groups (δH 0.66 and 0.99. Since Cissus rotundifolia extract has been 
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reported to contain components such as sterols. The olefinic signal at δ 5.28 (1H, J = 4.8 
Hz) appeared to be characteristic of the sterols, and it was assigned to the H-6 proton in 
the β–sitosterol (1) chemical skeleton. The 13C NMR spectra exhibited 29 carbon 
signals characteristic of phytosterols: 13C NMR (151 MHz, CDCl3) δ 140.77, 121.74, 71.82, 
56.78, 56.06, 50.14, 45.84, 42.34, 42.32, 39.79, 37.27, 36.52, 36.16, 33.95, 31.93, 31.92, 31.68, 
29.72, 29.15, 28.27, 26.07, 24.32, 23.08, 21.10, 19.84,19.04, 18.79, 12.00, 11.88. In addition 
to 2D, DEPT135 showed that 11 carbon signal inverted as represent of CH2 group:  13C 
NMR (151 MHz, CDCl3) δ 121.75, 71.83, 56.78, 56.06, 50.13, 45.83, 42.31 (inverted), 
39.78 (inverted), 37.26 (inverted), 36.16, 33.95 (inverted), 31.91,31.67 (inverted), 29.73 
(inverted), 29.14, 28.27 (inverted), 26.06 (inverted), 24.32 (inverted), 23.07 (inverted), 21.98, 
21.10 (inverted), 19.82, 19.42, 18.79, 12.00,11.88.. These data corresponded with the 
structure of the β-sitosterol compound (Figure 2-2). The NMR data of compound 1 (β-
sitosterol ) is in agreement with the published values.28 
Compound 2 was isolated as white powder. 1H NMR spectra of 2 showed one 
methyl group signal at δ 3.72 (s, 3H) and a doublet signal at δ 2.84 (m, 1H) and 2.71 (d, 
J=1.2Hz, 1H). Further, it showed a proton signal at δ 4.54- 4.62 (d, J = 2.5 Hz, 3H) with a 
secondary alcoholic proton signal δ 2.09 (d, J = 49, 2.8 Hz, 1H). The 13C-NMR data of 
compound 2 showed the presence of seven carbon signals in addition to two carbon 
signals for acetone solvent at δ 30.03 and 202.07. The 13C-NMR data present two 
carbonyl signal at δ 174.25, 171.98 and two peaks showed at the olefinic region at δ 
110.23 and 145.33. One carboxylate methyl ester at δ 52.28.19 and C2 hydroxyl at 68.19 
ppm respectively. One carbon signal at δ 39.36 which was assigned to methylene CH2 
based on calculated NMR data and 2D NMR Dept 135 spectrum that showed signal at δ 
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39.36 (inverted). Stereochemistry at C-2 could not be established at this point, further X-
ray analysis to establish the chirality at C-2 at this point could not be conducted. The 
above data indicated that structure 2 was characterized as 1-methyl 4-vinyl 2-
hydroxysuccinate (Figure 2-2). The NMR data of compound 2 corresponds with the 
published values. These dicarboxylic acids derivatives are widespread in nature and often 
appear with other functional groups. In addition, several synthesized dicarboxylate have 
wide spread applications in food industry and supplement preparations.29  
Compound 3 was isolated as yellow powder. 1H NMR (600 MHz, CDCl3) spectra 
of 3 showed two methyl group signals at δ 3.81 (s, 3H) and 3.71 (s, 3H) and a hydroxyl 
group proton at δ 3.39 (s, 1H) with a doublet signal at δ 2.83 (ddd, J = 22.7, 16.4, 5.3 Hz, 
2H) and secondary alcoholic proton signal at δ 4.53 – 4.50 (m, 1H). The 13C-NMR data 
of compound 3 showed the presence of six carbon signals in addition to a carbon signal 
for chloroform CDCl3. The 13C-NMR data presented two carbonyl signals at δ 173.74 and 
171.03, and three oxy carbons signals at δ 67.24, 52.82 and 52.03 ppm, which correspond 
to the dimethyl ester and C-2. One carbon signal, at δ 38.44, was assigned as C2 as result 
of 2D NMR Dept 135 spectrum that showed signal at δ 38.44 (inverted). Stereochemistry 
at C-2 could not be established at this point, further X-ray analysis to establish the 
chirality at C-2 at this point could not be conducted. The above data indicated that 
structure 3 was characterized as 1,4-dimethyl 2-hydroxybutanedioate (Figure 2-2). The 
NMR data of compound 3 is in agreement with a cited literature value.30 
Compound 4 was isolated as white crystal. 1H NMR (600 MHz, Acetone) spectra 
of 4 showed carboxylic acid proton at δ 8.42 (s, 1H), and one methyl group signal at δ 
3.71 (s, 3H) with a doublet signal at δ 2.76 (ddd, J = 23.4, 16.2, 5.9 Hz, 2H) and 
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secondary alcoholic proton signal at δ 4.54 (dd, J = 7.2, 4.7 Hz, 1H). The 13C-NMR data 
of compound 4 showed the presence of five carbon signals, in addition to two carbon 
signals for acetone solvent. The 13C-NMR data presented two carbonyl signals at δ 
174.39 and 172.68, and two carboxylate methyl signals showed at δ 68.29 and 52.58 
ppm. One oxy-carbon signal at δ 39.36 which was assigned to C2 hydroxyl based on 
calculated NMR data and 2D NMR Dept 135 spectrum that showed signal at δ 39.36 
(inverted). Stereochemistry at C-2 could not be established at this point, further X-ray 
analysis to establish the chirality at C-2 at this point could not be conducted. The above 
data indicated that structure 4 was characterized as 3-hydroxy-4-methoxy-4-oxobutanoate 
(Figure 2-2). The NMR data of compound 4 is in agreement with the published values.31 
Compound 5 was isolated as a white powder, then identified using 1H, 13C and 2D 
NMR. 1H NMR (600 MHz, CDCl3) spectra of 5 showed two proton signals at δ 7.88 (s, 
1H) and 6.82 (s, 1H), assigned for C-1 and C-2. Then, a proton signal at δ 4.50 (d, 1H) 
assigned for CHOH carbon proton and at δ 2.84 (m, 1H) proton assigned for hydroxyl 
group proton. In addition, a signal proton showed at δ 3.74 (t, 3H) and δ 3.65 (m, 3H) 
assigned for C-3 and C-5 as two methyl groups. Two signal peaks showed at δ 2.78 (m, 
2H) and δ 2.70 (m, 2H) assigned for CH2 at C-6 and C-7. The 13C-NMR data of 
Compound 5 presented twelve carbon signals. Two carbonyl signals at δ 173.78 and 
171.15, and three methoxy carbons signal showed at δ 67.22, 52.42 and 52.12 ppm. One 
oxy-carbon signal at δ 38.44 which was assigned to C2 hydroxyl based on calculated 
NMR data and 2D NMR Dept 135 spectrum that showed signal at δ 39.36 (inverted). 
Stereochemistry at C-2 could not be established at this point, further X-ray analysis to 
establish the chirality at C-2 at this point could not be conducted. Two carbon peaks of 5 
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spectra showed at δ 132.34 and δ 115.29 assigned for C-3 and C-4. The above data 
indicated that structure 5 was characterized as Dimethyl-2-hydroxy-5-
methylenehexanedioate (Figure 2-2). The NMR data of compound 5 is in agreement with 
a cited literature value.32 
Compound 6 was isolated as a white powder, then identified using 1H, 13C and 2D 
NMR. 1H NMR (600 MHz, CDCl3) spectra of 6 showed proton signals at δ 4.72 (s, 1H) 
assigned for C-2 as and proton signal at δ 2.64 (m, 1H) assigned for hydroxyl group at C-
2. The 1H-NMR spectra of compound 6 also exhibited a signal corresponding to the 
proton connected to C-3, which appeared as a multiplet at δ 2.66-2.54 (m, 2H). The 13C 
NMR spectra of compound 6 exhibited 4 carbon signals δ 178.26, 175.55, 67.287 and 
39.36. At δ 178.26, AT δ 175.55 showed two carbon signals assigned for carbonyl groups 
at C-1 and C-4. Also, compound 6 spectra showed carbon peak at δ 67.287 and was 
assigned for methoxy group at C-2. Stereochemistry at C-2 could not be established at 
this point, further X-ray analysis to establish the chirality at C-2 at this point could not be 
conducted. Carbon peak signal showed up filed at δ 39.36 and was assigned to CH2 at C-
3. The above data indicated that structure 5 was characterized as 2-hydroxysuccinic acid 








2.6.2 Biological evaluation 
α-Glucosidases are a series of enzymes located on the intestinal brush-border. The 
source of important carbohydrates in diet (e.g. starch and sucrose) are hydrolyzed to 
monosaccharide (glucose and fructose) by α-glucosidase, and then absorbed into the 
blood to increase blood glucose level. Normally, these processes happen in the upper 
portion of the small intestine and greatly increase blood glucose concentration, especially 
in diabetic patients. 34 According to literature study proposed that α-Glucosidase 
inhibitors (e.g. acarbose) increases the duration time of carbohydrate absorption and 
flatten the blood-glucose concentrations. Therefore, acarbose have been used as the first-
line drugs in treatment of diabetes.34 In this study, the aims were to explore the active 
compound compared with acarbose and evaluate how this active compound inhibited α-
glucosidase activity. Hexane, ethyl acetate and aqueous extracts, cissus rotundifolia 
showed variable inhibition of alpha-glucosidase enzyme based on alpha-glucosidase 
inhibition assay. Alpha-glucosidase inhibition was measured in the concentration range 
of 12.5 mg/mL to 50 mg/mL for each fraction and 12.5 uM to 100 uM for each pure 
compound. As shown in figure 2-2, the ethyl acetate fraction exhibits significant 
inhibition effects on alpha-glucosidase enzyme at different concentrations of 12.50, 25, 
and 50 mg/mL, respectively, while the n- hexane fraction was found to have lowest 
inhibition activity. The aqueous fraction showed slight inhibition activity against alpha-
glucosidase enzyme. In addition, the ethyl acetate fraction showed a concentration-
dependent inhibitory effect on the alpha-glucosidase enzyme. These results obviously 
suggest that the ethyl acetate fraction possesses the highest inhibition activity and led us 
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to carry out a study to identify the active constituents that may contain potential 
antidiabetic compounds.  
The ethyl acetate fraction subjected to column chromatography on silica gel to give 
five main fractions (F1- F5). Fraction 1 afforded pure sitosterol compound 1 (Figure 2-
12). Both fractions 3 and 4 demonstrated the highest inhibition activity in a 
concentration-dependent manner. The bioassay guided purification of subfractions 
resulted in the isolation and identification of six compounds: SAA1 (1), SAA2 (2), SAA3 
(3), SAA4 (4), SAA5 (5) and SAA6 (6) (Figure 2-12). Compound 3 showed the most 
promise with significant inhibition 51 % of alpha-glucosidase enzyme activity. The dose-
dependent manner present at four different concentration 100, 50, 25 and12.5 uM of the 
promising compounds and acarbose was used as a positive control (figure 2-8).  
In most reports, the mechanism of the inhibition against α-glucosidase was not yet 
clear. 26 In our experiments, six compounds isolated from Cissus rotundifolia showed 
different degree of activity against α-glucosidase.1,4-Dimethyl 2-hydroxybutanedioate 
(3) and 3-hydroxy-4-methoxy-4-oxobutanoate (4) had promising inhibition activity, and 
that might be because of C-2 hydroxyl group and dimethyl carboxylate at C-1 and C-4 in 
compound 3 that also strengthen α-glucosidase inhibition activity. At the same time, from 
compounds 2, 5 and 6’s structures, we inferred that if dimethyl group at C-1 and C-4 
were changed, it might cut down α- glucosidase inhibition activity. The difference 
inhibition activity between compound 2 and compound 3 could be related to the 
structural difference at C-4 the vinyl ester). However, the increase of compound 3 
inhibition activity could be attributed to the dicarboxylate methyl ester at C-1 and C-4. It 
is worth mentioning that dimethyl ester is relatively non-polar and therefore the polarity 
 62 
difference between active and nonactive compounds could be the reasons of this 
differences in the inhibition activity. The data from this study also indicated that 1,4-
dimethyl 2-hydroxybutanedioate (3), as the most effective compound, displayed a 
significantly inhibitory activity against α-glucosidase. All the findings indicated that 
cissus rotundifolia has potential activity for treatment of diabetes, and 1,4-dimethyl 2-




Cissus rotundifolia (Vitaceae), called Algalaf in Arabic, is used in Saudi folk 
medicine for the treatment of skin, malaria and control of diabetes. The chemical 
constituents were examined to determine chemical profile and potential antidiabetic 
activity. In the present study, bioassay-guided fractionation and purification were used to 
isolate the antidiabetic compounds of an extract of Cissus rotundifolia leaves. All 
fractions, sub-fractions and pure compounds were screened for their antidiabetic activity 
against the alpha-glucosidase enzyme. The highest inhibition activity was found to be in 
the ethyl acetate fraction, resulting in the isolation of six compounds identified as 
sitosterol (1), SAA2 (2), SAA3 (3), SAA4 (4) and SAA5 (5). Among the compounds 
isolated and tested for the first time, SAA3 and SAA4 showed potent antidiabetic 
activities through inhibition of the alpha-glucosidase enzyme different concentrations. 







Inhibitory activity for cissus rotundifolia fractions against alpha-glucosidase enzyme  
Figure 2-3 : Alpha-glucosidase enzyme inhibition of Cissus rotundifolia fractions 
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compared with Acarbose as positive control, represented in orange, to show the inhibition of alpha-glucosidase 
enzyme activity. 
 
Figure 2-5 : Ethyl acetate sub-fractions (3 & 4) at three different concentrations (10, 5, 2.5 mg/l), represented in blue,  
compared with Acarbose as positive control, represent in orange, to show the inhibition of alpha-glucosidase enzyme 
activity. 
 
Figure 2-6 : Ethyl acetate sub-fraction (5) at three different concentrations (10, 5, 2.5 mg/l), represented in blue, 
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Inhibitory activity for isolated compounds against alpha-glucosidase enzyme. 
 
Figure 2-7 : Isolated compound (1) at four different concentrations (100, 50, 25, 12.5 µM), represented in blue, 
compared with Acarbose as positive control, represented in orange, to show the inhibition of alpha-glucosidase 
enzyme activity. 
 
Figure 2-8 : Isolated compound (2) at four different concentrations (100, 50, 25, 12.5 µM), represented in blue, 




Figure 2-9 : Isolated compound (3) at four different concentrations (100, 50, 25, 12.5 µM), represented in blue, 
compared with Acarbose as positive control, represented in orange, to show the inhibition of alpha-glucosidase 
enzyme activity.  
 
 
Figure 2-10 : Isolated compound (4) at four different concentrations (100, 50, 25, 12.5 µM), represented in blue, 





Figure 2-11 : Isolated compound (5) at four different concentrations (100, 50, 25, 12.5 µM), represented in blue, 




Figure 2-12 : Isolated compound (6) at four different concentrations (100, 50, 25, 12.5 µM), represented in blue, 






                                
                         
 
 












1. Organization, W. H., WHO guidelines on good agricultural and collection 
practices [GACP] for medicinal plants. World Health Organization: 2003. 
2. Rishton, G. M., Natural products as a robust source of new drugs and drug leads: 
Past successes and present day issues. The American journal of cardiology 2008, 101 
(10), S43-S49. 
3. Brahmachari, G., Natural products in drug discovery: impacts and opportunities—
an assessment. In Bioactive natural products: opportunities and challenges in medicinal 
chemistry, World Scientific: 2012; pp 1-199. 
4. Petrovska, B. B., Historical review of medicinal plants’ usage. Pharmacognosy 
reviews 2012, 6 (11), 1. 
5. Patel, D.;  Prasad, S. K.;  Kumar, R.; Hemalatha, S., An overview on antidiabetic 
medicinal plants having insulin mimetic property. Asian Pacific journal of tropical 
biomedicine 2012, 2 (4), 320-330. 
6. Kattge, J.;  Diaz, S.;  Lavorel, S.;  Prentice, I. C.;  Leadley, P.;  Bönisch, G.;  
Garnier, E.;  Westoby, M.;  Reich, P. B.; Wright, I. J., TRY–a global database of plant 
traits. Global change biology 2011, 17 (9), 2905-2935. 
7. Katiyar, C.;  Gupta, A.;  Kanjilal, S.; Katiyar, S., Drug discovery from plant 
sources: An integrated approach. Ayu 2012, 33 (1), 10. 
 70 
8. Abdullah, M.; Merdan, A., Distribution and ecology of the mosquito fauna in the 
southwestern Saudi Arabia. Journal of the Egyptian Society of Parasitology 1995, 25 (3), 
815-837. 
9. Patel, D.;  Prasad, S.;  Kumar, R.; Hemalatha, S., An overview on antidiabetic 
medicinal plants having insulin mimetic property. Asian Pacific journal of tropical 
biomedicine 2012, 2 (4), 320-330. 
10. Rupeshkumar, M.;  Kavitha, K.; Haldar, P. K., Role of herbal plants in the 
diabetes mellitus therapy: An overview. Int J Appl Pharm 2014, 6 (3), 1-3. 
11. Fernandes, G.; Banu, J., Medicinal properties of plants from the genus Cissus: A 
review. Journal of Medicinal Plants Research 2012, 6 (16), 3080-3086. 
12. Said, A. A.;  Aboutabl, E. A.;  El Awdan, S. A.; Raslan, M. A., Proximate 
analysis, phytochemical screening, and bioactivities evaluation of Cissus rotundifolia 
(Forssk.) Vahl.(Fam. Vitaceae) and Sansevieria cylindrica Bojer ex Hook.(Fam. 
Dracaenaceae) growing in Egypt. Egyptian Pharmaceutical Journal 2015, 14 (3), 180. 
13. Brizicky, G. K., The genera of Vitaceae in the southeastern United States. Journal 
of the Arnold Arboretum 1965, 46 (1), 48-67. 
14. Kumar, D.;  Kumar, S.;  Gupta, J.;  Arya, R.; Gupta, A., A review on chemical 
and biological properties of Cayratia trifolia Linn.(Vitaceae). Pharmacognosy reviews 
2011, 5 (10), 184. 
15. Jeandet, P.;  Douillet-Breuil, A.-C.;  Bessis, R.;  Debord, S.;  Sbaghi, M.; Adrian, 
M., Phytoalexins from the Vitaceae: biosynthesis, phytoalexin gene expression in 
transgenic plants, antifungal activity, and metabolism. Journal of Agricultural and food 
chemistry 2002, 50 (10), 2731-2741. 
 71 
16. Onyechi, U. A.;  Judd, P. A.; Ellis, P. R., African plant foods rich in non-starch 
polysaccharides reduce postprandial blood glucose and insulin concentrations in healthy 
human subjects. British Journal of Nutrition 1998, 80 (5), 419-428. 
17. Alzoreky, N.; Nakahara, K., Antibacterial activity of extracts from some edible 
plants commonly consumed in Asia. International journal of food microbiology 2003, 80 
(3), 223-230. 
18. Omwenga, E.;  Okemo, P.;  Mbugua, P.; Ogol, C., Ethnobotanical survey and 
antimicrobial evaluation of medicinal plants used by the Samburu community (Kenya) 
for treatment of diarrhorea. 2009. 
19. Newman, D. J.; Cragg, G. M., Natural products as sources of new drugs over the 
last 25 years. Journal of natural products 2007, 70 (3), 461-477. 
20. Chobanian, A. V.;  Bakris, G. L.;  Black, H. R.;  Cushman, W. C.;  Green, L. A.;  
Izzo, J. L.;  Jones, D. W.;  Materson, B. J.;  Oparil, S.; Wright, J. T., Seventh report of the 
joint national committee on prevention, detection, evaluation, and treatment of high blood 
pressure. hypertension 2003, 42 (6), 1206-1252. 
21. Timmons, S. A.;  Posluszny, U.; Gerrath, J. M., Morphological and anatomical 
development in the Vitaceae. X. Comparative ontogeny and phylogenetic implications of 
Cissus quadrangularis L. Botany 2007, 85 (9), 860-872. 
22. Korish, M., Nutritional evaluation of wild plant Cissus rotundifolia. Italian 
Journal of Food Science 2016, 28 (1), 43-49. 
23. Ruphin, F. P.;  Baholy, R.;  Emmanuel, R.;  Amelie, R.;  Martin, M.-T.; Koto–te-
Nyiwa, N., Isolation and structural elucidation of cytotoxic compounds from the root 
 72 
bark of Diospyros quercina (Baill.) endemic to Madagascar. Asian Pacific Journal of 
Tropical Biomedicine 2014, 4 (3), 169-175. 
24. Patil, P.;  Mandal, S.;  Tomar, S. K.; Anand, S., Food protein-derived bioactive 
peptides in management of type 2 diabetes. European journal of nutrition 2015, 54 (6), 
863-880. 
25. Apostolidis, E.;  Kwon, Y.-I.;  Ghaedian, R.; Shetty, K., Fermentation of milk and 
soymilk by Lactobacillus bulgaricus and Lactobacillus acidophilus enhances functionality 
for potential dietary management of hyperglycemia and hypertension. Food 
biotechnology 2007, 21 (3), 217-236. 
26. Slama, G.;  Elgrably, F.;  Sola, A.;  Mbemba, J.; Larger, E., Postprandial 
glycaemia: a plea for the frequent use of delta postprandial glycaemia in the treatment of 
diabetic patients. Diabetes & metabolism 2006, 32 (2), 187-192. 
27. Subramanian, R.;  Asmawi, M. Z.; Sadikun, A., In vitro α-glucosidase and α-
amylase enzyme inhibitory effects of Andrographis paniculata extract and 
andrographolide. Acta Biochim Pol 2008, 55 (2), 391-398. 
28. Chaturvedula, V. S. P.; Prakash, I., Isolation of Stigmasterol and?-Sitosterol from 
the dichloromethane extract of Rubus suavissimus. International Current Pharmaceutical 
Journal 2012, 1 (9), 239-242. 
29. Lanning, W. C.; Gall, J. W., In situ gelation of polymers during waterflooding. 
Google Patents: 1972. 
30. Miyazawa, M.;  Anzai, J.;  Fujioka, J.; Isikawa, Y., Insecticidal compounds 
against Drosophila melanogaster from Cornus officinalis Sieb. et Zucc. Natural product 
research 2003, 17 (5), 337-339. 
 73 
31. He, X.-J.;  Lobkovsky, E.; Liu, R. H., (R*)-Methyl 3-carboxy-2-
hydroxypropanoate. Acta Crystallographica Section E: Structure Reports Online 2005, 
61 (12), o4104-o4106. 
32. Gerster, M.;  Audergon, L.;  Moufid, N.; Renaud, P., Simple and efficient 
stereocontrol of radical allylations of β-hydroxy esters. Tetrahedron letters 1996, 37 (35), 
6335-6338. 
33. Wishart, D. S.;  Knox, C.;  Guo, A. C.;  Eisner, R.;  Young, N.;  Gautam, B.;  
Hau, D. D.;  Psychogios, N.;  Dong, E.; Bouatra, S., HMDB: a knowledgebase for the 
human metabolome. Nucleic acids research 2009, 37 (suppl_1), D603-D610. 
34. Mertes, G., Efficacy and safety of acarbose in the treatment of type 2 diabetes: 




3 CHAPTER THREE: IN-VITRO EVALUATION OF ANTI-DIABETIC 
ACTIVITY OF ISOLATED COMPOUNDS. 
3.1 Introduction 
Diabetes mellitus is a metabolic disease characterized by high blood glucose level. 
The major risk of diabetes is obvious based on the dramatically high distribution rate of 
this disease. Recently, current estimations showed that the number of diabetics will 
increase up to 439 million in 2030.1, 2The majority of diabetics, more than 90%, are type 
2 diabetics.3 Type 2 diabetes mellitus (T2DM) is characterized by insulin resistance in the 
hepatic and peripheral tissues. Glucose transporter 4 (GLUT4) plays a main role in the 
pathophysiology of T2DM4. Generally, it is defective expression or translocation to the 
peripheral cell plasma membrane in type 2 diabetes mellitus patients that delays the 
entrance of glucose into the cell for energy production.5 Type 2 diabetes (T2DM) is 
identified by insulin resistance and a progressive weakening in β-cell function.6, 7 
Recently, it has been reported that insulin resistance is one of the most important factors 
in the pathogenesis of type 2 diabetes, which is known not only by reduced 
responsiveness of the peripheral target tissues like liver, skeletal muscle and adipose 
tissue to insulin, but also by a remarkable decrease in glucose uptake and utilization.8, 9 
Therefore, inducing glucose uptake in the above three key tissues is one of the main 
effective therapeutic approaches for treating Type 2 diabetes.10 Meanwhile, natural 
products are the main source of drug discovery.11 
 75 
Cissus rotundifolia (fam. Vitaceae) is one of the traditional medicinal plants widely 
distributed in south western part of Saudi Arabia. C. rotundifolia  leaves have been used 
as a folk herbal drug to treat skin, bacterial infections, inflammatory conditions and flu in 
alternative medicine.12, 13 It has also been reported to possess antibacterial activity when 
tested against E. coli, S. infantis, S. aureus and L. monocytogenes in study where only the 
extract of edible plant were screened for their antibacterial activity however the 
investigation of specific active compound need future studies.14.15 Cissus Rotundifolia as 
a crude extract has been reported to possess biological activities.16, 17,  18 For example, 
antimalarial and anti-inflammatory effects as an extract.16, 19 However, there is no report 
on the antidiabetic activity of C. Rotundifolia  leaves antidiabetic activity such as glucose 
uptake or metabolism. Therefore, this study was to investigate whether the leaves of C. 
rotundifolia fractions possessed antidiabetic activity or not through inducing glucose 
uptake. 
3.2 Glucose uptake pathway 
Through an intracellular pathway, insulin induces translocation of glucose 
transporters (GLUTs) into the cell membrane of the cells.20-22 Actually, the most 
important effects of insulin on glucose metabolism are the regulation of GLUT4 
trafficking and, consequently, glucose uptake.23 Furthermore, glucose transport plays the 
essential role in insulin-regulated glucose metabolism, including glycogen synthesis, 
glycolysis and lipogenesis, where a dysfunction in this route in muscle and adipose tissue 
signifies an important defect in the insulin action.24, 25 Insulin receptor is a heterotetramer, 
involving two extracellular α subunits (binding fraction) and two transmembrane β 
subunits (with intrinsic tyrosine kinase) linked by disulfide bonds.26 In insulin-responsive 
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tissues, such as liver, skeletal muscle and adipose tissue, the action of insulin begins by 
binding to its specific receptor.27 The activation of the insulin receptor makes a structural 
change in the α subunit, leading to autophosphorylation of a tyrosine kinase domain of β 
subunits and subsequent tyrosine phosphorylation of numerous protein intermediates, 
involving insulin receptor substrate (IRS -1, 2, 3 and 4).28, 29 Both of these 
phosphorylated substrates identify and bind to domains with homology SH2, especially 
phosphatidylinositol-3-kinase (PI3-K).28, 30 Then, upon attachment to the cell surface, 
protein kinase B (AKT) is activated, resulting in the AKT-dependent phosphorylation of 
many substrates. In addition to glucose uptake, virtually all of insulin's metabolic effects 
are regulated by AKT.31 For example, AKT-dependent phosphorylation of glycogen 
synthase kinase 3 (GSK-3β) leads to the activation of glycogen synthase and enhances 
glucose storage as glycogen.32, 33 Generally, the most important effects of insulin on 
glucose metabolism are the regulation of GLUT4 trafficking and, consequently, glucose 
uptake.23 Moreover, glucose transport plays the essential role in insulin-regulated glucose 
metabolism. Therefore, the isolated compounds with potential antidiabetic activity from 
cissus rotundifolia extract conduct to an in vitro evaluation of glucose uptake induction 
through glucose uptake assay.  
 
3.3 Aim of the study 
Natural bioactive compounds have a long history of effective use in the treatment 
of diabetes mellitus. Cissus rotundifolia (Vitaceae) have been used locally (in 
southwestern part of Saudi Arabia), for the treatment of different ailments such as skin 
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disease, malaria and hypoglycemia.34. Although the hypoglycemic effect of C. 
rotundifolia leaves extract has been reported, the exact mechanism of this effect has not 
been fully discovered. 19 In fact, the most important effects of insulin on glucose 
metabolism are the regulation of GLUT4 trafficking and consequently glucose uptake.23 
Moreover, glucose transport plays the essential role in insulin-regulated glucose 
metabolism, including glycogen synthesis, glycolysis and lipogenesis. The present work 
aims to study the effect of fractions and the isolated bioactive compounds of Cissus 
rotundifolia extract on glucose uptake in liver cell lines (HepG2). This study evaluates 
the glucose uptake activity of cissus rotundifolia leaves methanolic extract fractions, sub 
fractions and the isolated compounds in HepG2 cell in vitro. The isolated compounds, 
cell viability and antidiabetic activity of the extract were also discussed.  
3.4 Materials and methods 
3.4.1 Reagents 
Dimethyl sulfoxide (DMSO), 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium-bromide (MTT), sodium dodecyl sulphate (SDS). Fetal bovine serum (FBS) 
was purchased from HyClone (Logan, UT, USA). Dulbecco’s modified Eagle medium 
(DMEM), phosphate buffered saline (PBS) 1X solution and trypsin were purchased from 
Gibco (Grand Island, NY, USA). Glucose (Oxidase) Liquid Reagents were purchased 
from Fisher Scientific (Turnberry Hanover, IL, USA). Insulin solution from bovine 
pancreas at 10 mg/mL insulin, pH 8.2, BioReagent, sterile-filtered, suitable for cell 
culture was used as positive control. 
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3.4.2 Extracts and Isolated Compounds 
Fresh leaves of Cissus rotundifolia were collected in June 2016 from the area near 
Abha, Saudi Arabia. The plant was botanically authenticated, and a voucher specimen 
was deposited in Pharmacognosy Department Herbarium, College of Pharmacy, King 
Khaled University, Abha, Saudi Arabia. 
3.4.3 Preparation of plant extracts and fractions 
The leaves of Cissus rotundifolia (7 kg) were cut into small pieces and 
homogenized in methanol (a blender was filled to third (1/3) volume with leaves, 1.5 L of 
methanol was added, and the mixture was homogenized for 5 min). Then, the mixture 
was macerated in methanol for 72 hours. The methanol extract was filtered, concentrated 
under reduced pressure at 40°C using a rotary evaporator and lyophilized to afford a 
residue. The dried methanol extract (210 g) was dispersed in deionized water (500 ml) 
and partitioned sequentially with n-hexane (500 ml×3) and ethyl acetate (500 ml×3).The 
combined solvent of each partitioned extract was concentrated under reduced pressure at 
40°C using the rotary evaporator and freeze dried for 72 hours to yield an n-hexane 
fraction (32 g), an ethylacetate fraction (20 g) and the remainder of the water fraction 
(158 g). 
3.4.4 Cell Culture  
A human cancer liver cell line (HepG2) was obtained from American Type Cell 
Culture (ATCC, Rockville, MD, USA). The HepG2 cell line was maintained at 37°C in a 
humidified atmosphere of 5% CO2 in a DMEM medium containing 10% fetal bovine 
serum and antibiotics (100 IU/mL penicillin and 100 µg/ml). 
 79 
3.4.5 Cell viability assay 
Cell viability was determined by the MTT method, as previously described, with a 
modification. Briefly, cells (1 ×104cells/well) were seeded into a 96-well plate and 
allowed to attach to the well overnight. Fractions were then added at different 
concentrations (100, 50, 25, 12, 50 mg/ml) and cells were incubated for a further 24 
hours. After incubation, 10 µL of 5 mg/mL of MTT dye was added to the cells for 4 
hours at 37°C, followed by the addition of 100 µL of 10% SDS in 0.01 N HCl as a 
solubilizing agent. The absorbance at 570 nm was recorded using an ELISA microplate 
reader. The results of viability were expressed as a percentage of the control. 
3.4.6 Glucose uptake assay 
Glucose uptake using human liver cancer cell line (HepG2) as liver tissue plays a 
significant role in controlling blood glucose level. Briefly, HepG2 cells were seeded in 
96-well plate with some wells left blank. Then, when the cells gained confluence, the 
medium was exchanged for DMEM containing 0.2% BSA and incubated for 18 hours. 
After incubation, the cells were treated with DMEM containing 0.2% BSA with the 
selected concentrations of test samples for another 24 h. Then 10 uL of medium was 
removed from each well and placed into a new 96-well plate that contained 200 uL of 
glucose oxidase reagent (Glucose CII-Test, IL, USA). Finally, the plate was incubated at 
37C for 15 min and the optical density (OD) was measured at 490 nm using a microplate 
reader. The percent of glucose uptake was estimated by subtracting the glucose 
concentrations of the blank wells from the remaining glucose in the cell plated wells. 
Insulin (10 mg/mL) was used as positive control. 
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3.5 Results and Discussion 
3.5.1 Cell viability assay 
The cell viability of the methanol extract and the fractions of ethylacetate and hexane 
from Cissus rotundifolia on HepG2 cells was assessed by MTT assay (Figure 3-1). At the 
concentration of 100 mg/mL, the cell viability of the extract was about 85% for HepG2 
and the cell viability of the ethylacetate fraction was evaluated at concentration 100, 50, 
25, 12, 50 mg/ml respectively as presented in figure 3-1. Cissus rotundifolia extracts 
toxicity was tested in vitro in HepG2 cell line using MTT assay. Extract concentrations 
that kept at least 80% cell viability were considered as safe. MeOH extract (Fig. 3-1) was 
found to be safe up to 100 mg/ml where’s hexane (Fig. 3-1) and aqueous extract (Fig. 3-
1) were found to be lower than 80% cell viability at 100 mg/ml. Ethyl acetate extract 
(Fig. 3-1) was found to be safe up to 100 mg/ml that showed 86% cell viability at 100 
mg/ml.  Accordingly, all the efficacy studies for the three extracts were performed at safe 
concentrations. Therefore, different doses of the methanol extract and fractions from C. 





Cell Viability effect of Cissus rotundifolia on HepG2 cell line  
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Figure 3-1 : Comparison of cell viability results obtained using MTT. Cells were treated with 12.5-100 mg/ml of each 
fraction represent in (12.5 (blue), 25 (orange), 50 (gray), and 100 (yellow)). MTT assay was used to measure the cell 
viability %.. 
 
3.5.2 Glucose uptake assay 
The effect of methanol, ethylacetate and hexane extracts of C. rotundifolia leaves on 
glucose uptake in HepG2 cells are illustrated in Figure 3-2. The ethylacetate fraction 
showed a significant induction of glucose uptake in HepG2 cells with a value of 27% at 
the concentration of 50 mg/mL compared with insulin as positive control. Insulin 
increased glucose uptake in HepG2 cells of about 18%, while the hexane fraction showed 
14 % inducing glucose uptake activity and the aqueous fraction showed 20 % induction 
of glucose uptake activity in HepG2 cells. So, the result indicates that the ethylacetate 
fraction has a promoting effect on HepG2 cells and the ethylacetate fraction has the most 
promising induction of glucose uptake, represented in figure 3-2. Moreover, the present 
study was conducted to evaluate the effect of six compounds were isolated from cissus 
rotundifolia on glucose uptake activity in HepG2 cell line, and insulin used as positive 
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rotundifolia. The results indicate that the isolated compounds 3-hydroxy-4-methoxy-4-
oxobutanoate (SAA4) and 1,4-dimethyl 2-hydroxybutanedioate (SAA3) have promising 
glucose uptake inducing activity (Figure 3-4). 3-Hydroxy-4-methoxy-4-oxobutanoate 
(SAA4) has the most significant induction of glucose uptake activity about 26% at 100 
uM concentration. Additionally, isolated compound 1,4-dimethyl 2-hydroxybutanedioate 
(SAA3) showed the enhancement in glucose uptake by 24% at 100 uM concentration. 
While the rest compounds β-sitosterol (SAA1), dimethyl-2-hydroxy-5-
methylenehexanedioate (SAA5), and 2-hydroxysuccinic acid (SAA6) showed no effect 
on glucose uptake inducing activity in comparison to control in HepG2 cell line (figure 3-
7). Compound 4 was found to be most promising compound over the isolated compounds 
for inducing glucose uptake in liver cell line.  Generally, liver is major site of glycogen 
storage and thus, glucose uptake activity is important to maintain normal blood glucose 
level35. Present study showed that the isolated bioactive compounds SAA4 and SAA3 
enhance the glucose uptake in HepG2 at dose dependent manner which may be due to its 
effect on the receptors on the cell membrane in liver cell line (HepG2). Future in vivo 
study to confirm our data is important to support the novel glucose uptake induction of 
these compounds. 
3.6 Conclusion 
In the present study, bioassay-guided fractionation and purification were used to isolate 
the antidiabetic compounds of an extract of Cissus rotundifolia leaves as mentioned in 
Chapter2. All fractions, sub-fractions and pure compounds were screened for their 
antidiabetic activity through glucose uptake inducing activity on the cell. The highest 
inducing activity was found to be in the ethyl acetate fraction and two isolated c 
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compounds SAA3 (3), SAA4 (4). Compounds SAA4 and SAA3 showed potential 
antidiabetic activity through inhibition of glucose uptake in comparison to insulin. Future 
investigation of antidiabetic activities of isolated compounds in vivo to elucidate the 




Effect of Cissus rotundifolia fractions on glucose uptake
Figure 3-2 : Effect of Cissus rotundifolia fractions on glucose uptake. Fractions of Methanol, Ethylacetate, hexane and 
aqueous represent in orange, compared with insulin as positive control represent in gray to show the induction of 



































Figure 3-3 : Isolated compound (1) at four different concentrations (100, 50, 25, 12.5 µM), represented in orange, 
compared with insulin as positive control, represented in gray, to show the induction of glucose uptake activity. 
 
Figure 3-4 : Isolated compound (2) at four different concentrations (100, 50, 25, 12.5 µM), represented in orange, 







































3-5 : Isolated compound (3) at four different concentrations (100, 50, 25, 12.5 µM), represented in orange, compared 
with insulin as positive control, represented in gray, to show the induction of glucose uptake activi









































compared with insulin as positive control, represented in gray, to show the induction of glucose uptake activity..
 
Figure 3-7 : Isolated compound (5) at four different concentrations (100, 50, 25, 12.5 µM), represented in orange, 
compared with insulin as positive control, represented in gray, to show the induction of glucose uptake activity.. 
 
Figure 3-8 : Isolated compound (6) at four different concentrations (100, 50, 25, 12.5 µM), represented in orange, 
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4 CHAPTER FOUR: IN-SILICO MOLECULAR MODELING STUDY OF 
ISOLATED COMPOUNDS TARGETING CITRIC ACID CYCLE ENZYMES 
4.1 Introduction 
Glucose homeostasis is physiologically maintained by balance between glucose 
production by liver and glucose consumption by the peripheral tissues.1 Hepatic glucose 
production and glucose utilization is controlled by insulin, so, in non-insulin-dependent 
diabetes mellitus (NIDDM), hepatic glucose production is high and demonstrates a 
positive correlation with concentrations of glucose in plasma.2 Moreover, increases in 
hepatic glucose production are considered the principal cause of fasting hyperglycemia in 
NIDDM.3 In the liver, two processes produce glucose (gluconeogenesis and 
glycogenolysis); however, gluconeogenesis develops to be significantly increased in 
NIDDM.3 When the process of gluconeogenesis increases, it will further cause increased 
hepatic glucose production and a positive correlation between the rates of 
gluconeogenesis and fasting plasma glucose concentration has been discovered in 
NIDDM subjects.4, 5Therefore, reduced hepatic glucose production also plays an 
important role in controlling blood glucose level and is considered a new target for 
antidiabetic research.6 Gluconeogenesis begins in the mitochondria through citric 
acid cycle intermediates, starting throughout conversion to oxaloacetate, which can also 
function as substrates for gluconeogenesis.7 Gluconeogenesis is a pathway involving a 
couple of enzyme-catalyzed reactions.8 This pathway starts in the mitochondria or 
cytoplasm based on the substrate being used.7 Gluconeogenesis begins with the formation 
of oxaloacetate from carboxylation of pyruvate. This reaction needs one molecule of ATP 
and it is catalyzed by an enzyme called pyruvate carboxylase.9 Pyruvate carboxylase is 
stimulated by high levels of acetyl-CoA.10 Over the reaction of the citric acid cycle, 
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Malate is the intermediate oxidized to oxaloacetate using NAD+ in the cytoplasm, where 
other steps of gluconeogenesis show.11 Oxaloacetate is decarboxylated and 
phosphorylated to generate phosphoenolpyruvate by phosphoenolpyruvate 
carboxykinase.12 
Gluconeogenesis provides stable blood glucose levels between meals; however, it 
is found to be high in diabetic patients. Gluconeogenesis also helps maintain glucose 
levels when on a diet low in carbohydrates.13 Therefore, based on the similarity in the 
chemical structure between the isolated compounds from cissus rotundifolia and citric 
acid cycle substrates, our hypothesis that molecular modeling to study binding affinity of 
the isolated compound with citric acid cycle enzymes could reveal potential mechanism 
of compounds isolated in our study to inhibit gluconeogenesis  and control 
hyperglycemia through inhibition of hepatic glucose production. 
 
4.2 Citric acid cycle (Kreb’s Cycle) 
The citric acid cycle, also called the Krebs or tricarboxylic acid cycle, is a series of 
reactions in mitochondria that result from oxidization of the acetyl moiety of acetyl-CoA 
to CO2 and decreases coenzymes that are reoxidized through the electron transport chain 
related to the formation of ATP.14 The tricarboxylic acid cycle is a pathway for the 
oxidation of carbohydrates, proteins and lipids because glucose, most amino acids and 
fatty acids are metabolized to acetyl-CoA or intermediates of the cycle.15 The citric acid 
cycle has a fundamental role in the gluconeogenesis process that is considered the main 
pathway of the hepatic production of glucose. These processes occur in the liver tissues, 
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the abnormally increased rate of hepatic gluconeogenesis contributes to hyperglycemia 
in diabetes.13, 16 
4.3 Steps of the citric acid cycle  
Several steps during the citric acid cycle occur through enzymatically catalyzed 
reaction in order to generate the molecules produced.17 The molecules produced from the 
citric acid cycle, such as NADH, FADH, and ATP, are important as sources of energy, 
while the intermediate produce through the citric acid cycle are important in another 
process.18 For example, oxaloacetate is one of intermediates of the citric acid cycle that 
plays an essential role and is the starting point of the gluconeogenesis process to produce 
glucose.19 The steps of the citric acid cycle begin when acetyl CoA joins with 
oxaloacetate, four carbon molecules, to form a six-carbon molecule (citrate). This step is 
catalyzed by an enzyme called citrate synthase. The second step, which is a two-step 
process, occurs when citrate is converted into its isomer, isocitrate. This step is catalyzed 
by an aconitase enzyme and it involves the removal and then the addition of a water 
molecule, which is the reason that the citric acid cycle is sometimes defined as having 
nine steps rather than the eight. The third step, the enzyme isocitrate dehydrogenase 
catalyzes this step when the isomer of citrate, isocitrate, is oxidized and releases a 
molecule of carbon dioxide to form a five-carbon molecule called α-ketoglutarate. Next, 
the fourth step begins when α-ketoglutarate oxidizes and releases a molecule of carbon 
dioxide to form a four-carbon molecule. These four-carbon molecules pick up Coenzyme 
A, producing the unstable compound succinyl CoA. The enzyme, α-ketoglutarate 
dehydrogenase, is catalyzed in this forth step and also it is important in the regulation of 
the citric acid cycle. In step five in citric acid cycle, the CoA of succinyl CoA is 
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substituted by a phosphate group, then transferred to ADP to make ATP. The four-carbon 
molecule produced in this step is called succinate. The enzyme that catalyzes this step is 
the succinyl CoA synthetase enzyme. Then, in step six, succinate is oxidized, creating 
another four-carbon molecule called fumarate. An enzyme called succinate 
dehydrogenase catalyzes this step. The result of this reaction, two hydrogen atoms with 
their electrons, are transferred to FAD, forming FADH2. The enzyme involved in this 
step is implanted in the inner membrane of the mitochondrion, so FADH2 can transfer its 
electrons directly into the electron transport chain. Step seven in citric acid cycle involves 
the four-carbon molecule fumarate converting into another four-carbon molecule called 
malate. The Fumarase enzyme catalyzes this step. The last step of the citric acid cycle, 
step eight, creates oxaloacetate, a four-carbon compound formed by oxidation of the 
















Gluconeogenesis is a pathway to produce glucose in the human body.20 In diabetic 
patients, gluconeogenesis is active, especially during fasting, so the current target to 
control diabetic disease is to inhibit gluconeogenesis in order to manage hyperglycemia.21 
Gluconeogenesis is a process to produce glucose from precursors such as lactate, 
glycerol, pyruvate and amino acids.21, 22 A fasting condition requires synthesis of glucose 
from non-carbohydrate sources. Most precursors must enter the citric acid cycle at some 
point to be converted to oxaloacetate.3 Oxaloacetate is an intermediate of the citric acid 
cycle that is the starting material for gluconeogenesis.23  
 
 
Figure 4-2 : Citric acid cycle intermediate, Oxaloacetate, as starting material of Gluconeogenesis process 
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The citric acid cycle, or tricarboxylic acid cycle, has a fundamental role in the 
gluconeogenesis process that is considered the main pathway of the hepatic production of 
glucose. The citric acid cycle is a series of reactions in mitochondria that result from 
oxidization of the acetyl moiety of acetyl-CoA to CO2 and decreases coenzymes that are 
reoxidized through the electron transport chain related to the formation of ATP. The 
enzymes involving in citric acid cycle play important role in regulation of 
gluconeogenesis through catalyzes each step of the cycle to form the substrates. 
Oxaloacetate is a substrate of citric acid cycle and it is the starting material for 
gluconeogenesis. Although the properties of citric acid cycle enzymes have been studied, 
the reports of targeted small molecule modulators of the activity have been limited. 
Therefore, in this study the isolated compound and small analogs investigation of their 
binding affinity to citric acid cycle enzymes that might lead to a new discovery for 
inhibition activity of gluconeogenesis. 
. 
4.5 Molecular docking 
Molecular docking is a structure-based drug design approach. It is frequently used 
in the drug discovery process to determine the best matches between a receptor/target 
protein and a ligand/drug.24 The molecular docking method involves predicting the 
conformations and orientations of a molecule in the active site of target macromolecules 
and labeling the preferred configurations and conformations of molecules binding with 
the active site of target macromolecules.24 The two major purposes of molecular docking 
are right structural modeling and correct prediction of activity.25 Moreover, molecular 
docking has been used in different phases of the drug discovery pipeline, such as 
quantitative structure activity relationship, virtual combinatorial library generation, lead 
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optimization and discovery of a potential lead through virtual screening.25 In addition, the 
application of molecular molding has extended to the analysis of physico-chemical 
parameters of the ligand, including absorption, distribution, metabolism and 
elimination/toxicity using a variety of applications and programs.25, 26 Therefore, in this 
present study, we use computational molecular modeling tools to study and predict the 
interaction of isolated compounds from cissus rotundifolia extract analogs enriched with 
functionalities with citric acid cycle enzymes and gluconeogenesis enzyme PEPCK. 
 
4.6 Aim of the study 
The promising isolated compounds from cissus rotundifolia identified as the dicarboxylic 
aicds analogs showed similarity to malate structure (one of the main intermediates of 
citric acid cycle). Therefore, the similarity in the chemical structure prompt us to build a 
hypothesis for investigating the ability of the isolated compounds to inhibit the 
gluconeogenesis process through inhibition of the citric acid cycle, one of the main 
pathways to reduce the blood glucose level. The molecular docking process includes 
predicting the conformations and orientations of a molecule in the active site of target 
macromolecules and identifying the preferred configurations and conformations of 
molecules interacting with the active site of target macromolecules. In this study, we used 
molecular docking as one of the main strategies in the structure-based drug design 
approach, so we use computational molecular modeling tools to study and predict the 




4.7 Materials and methods 
 
4.7.1 Compounds 
 Six compounds were isolated from cissus rotundifolia as previously mentioned in 
Chapter 2. In addition to, 2-aminosuccinicamide, 4-methoxy-2,4, dioxobutanic acid and 
levulinic acid compounds. For docking, a vertical library of thirty analogs docked 
including metformin as standard. 
 
 
Figure 4-3: Chemical structure of Isolated compounds (1- 6) from Cissus rotundifolia extract. 
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4.7.2 Molecular modeling 
 Molecular modeling was completed using four application softwares (make 
receptor , Omega, Fred and Vida) using the method previously published by our group.27 
4.7.3 2D and 3D Structures  
A virtual library of thirty analogs and standard metformin compound, along with 
known antidiabetic therapies for the treatment of diabetic mellitus, were prepared using 
ChemOffice Ultra. The energies of the 3D structures were minimized using semi-
empirical PM3 calculations. The energy-minimized structures were then converted into 
pdb files, maintaining all heavy atoms. 
4.7.4 Generation of conformers 
The energy-minimized structures were combined into a single continuous pdb file 
to be used as an input for Omega. The Omega utility uses the MMFF94 force field to 
form multiple conformations for each input ligand in the library in order to induce ligand 
flexibility in an otherwise rigid model. 
4.7.5 Receptor preparation 
 
All of the citric acid cycle enzymes and phosphonyl pyruvate kinase enzyme were 
prepared for the molecular docking process. Citrate synthase (PDB ID: 1cts), aconitase 
(PDB ID: 7acn), isocitrate dehydrogenase (PDB ID: 3blw), alpha-ketoglutarate 
dehydrogenase (PDB: 2jGD), succinyl CoA synthetase (PDB: 2FP4), succinate 
dehydrogenase (PDB: 1neck), fumarase (PDB: 1fuo), malate dehydrogenase (PDB: 
1MLD) and phosphonyl pyruvate kinase enzyme (PECK) (PDB ID:  ) structures were 
downloaded from the RCSB Protein Data Bank and prepared for modeling using Fast 
Rigid Exhaustive Docking (FRED). The application allows for the creation of a grid box 
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by the mode selection pane and adjustment of its size using the mode controls. The box 
size would not exceed 50000–60000Å. Once the grid box size has been created, the 
receptor is ready for use in the docking calculations. 
4.7.6 Docking  
Multiple scoring functions were used in order to identify a consensus structure and 
score in the final output. The scoring functions involve Shapegauss, Chemgauss3, 
Oechemscore, Screen score and PLP. Snapshots and visualizations of the chemical 
interactions between the analogues and receptors were obtained using the VIDA 
application. 
4.8 Results and discussion 
4.8.1 Molecular modeling  
OpenEye Software sets (Fast Rigid Exhaustive Docking (FRED), make Receptor, 
Omega, FRED and VIDA) were used to run the molecular docking studies.27 The crystal 
structure of the citric acid cycle enzymes was used as a molecular target. A virtual library 
of compounds was docked into a ligand binding domain of all the eight enzymes involved 
in each step of the citric acid cycle in addition to phosphoenolpyruvate kinase protein 
(PECK). The molecular docking results showed that analog 2-aminosuccininamide 
(AN21), levulinic acid, and SAA4 compounds possess a high binding affinity on the 
fumarase enzyme. Levulinic acid formed a hydrogen bonding interaction between the 
carboxylic group at C-1 and the amino acid residue ASN135, in addition to another two 
hydrogen bonding interactions between the oxygen of carbonyl group at C-4 with the 
amino acid residues ASN141 and SER140 in fumarase (Figure 4.7). Meanwhile the 
isolated compound, SAA4, is one of the top compounds that showed high binding affinity 
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with the fumarase enzyme. The isolated compound SAA4 formed two hydrogen bonds 
between the oxygen on the groups at C-1and C-3 with SER139 and ASN141, respectively 
(Figure 4-8). Also, analog (AN21) exhibited a high binding affinity with no hydrogen 
bonding interaction (Figure 4.9). Meanwhile, SAA3 compound, which is an isolated 
compound from cissus rotundifolia, formed only one hydrogen bond interaction between 
the carboxylic group at C-1 and the amino acid residue SER140 in fumarase (Figure 
4.10). Alternatively, SAA4 and SAA3 compounds isolated from cissus rotundifolia 
extract showed a binding affinity to three of the citric acid enzymes targeted: isocitrate 
dehydrogenase, succinate dehydrogenase and succinyl CoA. The SAA4 isolated 
compound showed the highest binding affinity to isocitrate dehydrogenase in comparison 
to other isolated compounds and analogs. SAA4 formed hydrogen bonding interaction 
between C-1 and the amino acid residue HIS301 (figure 4.12). SAA3 compound showed 
a high binding affinity to the succinyl CoA enzyme forming two hydrogen bonding  
between the hydroxy group C-2 and carboxylate oxygen C-1 with the amino acid residue 
LYS172 and TYR173, respectively (figure 4.11). Meanwhile, analogs AN21 and 
levulinic acid compounds showed a high binding affinity with the malate dehydrogenase 
enzyme. The AN21 analog formed three hydrogen bond interactions between the amide 
group at C-3 with the amino acid residue ASN118; in addition, two hydrogen bonds 
appeared between the oxygen of carbonyl group at C-1 with two amino acid residues, 
THR211 and ARG80, respectively (Figure 4.13). The isolated compound SAA3 showed 
a high binding affinity to malate dehydrogenase, which exhibited a hydrogen bond 
interaction to malate dehydrogenase enzyme between the hydroxyl group at C-2 with the 
amino acid reside ALA223 (Figure 4.14). On the other hand, compound SAA2 showed 
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less binding affinity on fumarase enzyme and show no hydrogen bond to malate 
dehydrogenase. Structural differences between SAA3 and SAA2 are obvious reason for 
different binding activities. SAA5 does not show binding affinity to fumarase enzyme. 
Higher binding affinity of SAA3 could be attributed to its structural difference from other 
compounds at C-1 and C-4. Furthermore, binding affinity study showed that C-2 hydroxy 
group hydrogen bond to malate dehydrogenase enzyme is the key point behind higher 
binding affinity to malate dehydrogenase enzyme.  Phosphoenolpyruvate protein kinase 
(PEPK) plays an important role in the gluconeogenesis process. The results of docking of 
PEPK with the isolated compounds from cissus rotundifolia and analogs showed that 
SAA3 possesses a high binding affinity. SAA3 formed hydrogen bonding interaction 
between C-1 and the residue of the amino acids VAL335, SER286 and LYS290. (Figure 
4.15). Generally, the result of the top twenty analogs showed a high binding affinity to 
citric acid cycle enzymes and the phosphoenolpyruvate protein kinase. Analogs (AN21), 
(AN4) and Levulinic acid, in addition to, the isolated compounds from cissus rotundifolia 
(SAA4 and SAA3) showed the most promising binding affinity to more than one target of 
enzymes that involved in citric acid cycle, so these molecules based on molecular 
docking result need for further studied using biological evaluation in order to investigate 




In this study, isolated compounds from cissus rotundifolia and their analogs, 
including analogs with metformin like functionalities, were studied and their ability to 
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bind to the citric acid cycle enzymes were analyzed using molecular modeling. The 
molecular docking results showed that analog (AN21), levulinic acid and the isolated 
compound SAA4 compounds possess a high binding affinity on the fumarase enzyme, In 
addition to the isolated compound SAA3 and SAA4 showed high binding affinity on 
malate dehydrogenase enzyme, suggesting that they may have potential for treating 
diabetes mellitus through inhibition of citric acid cycle based on the high binding affinity 
of these molecule to fumarase and malate dehydrogenase enzymes. More interestingly, 
our molecular modeling and binding affinity results on the isolated compounds suggests 
they may have inhibition activity for gluconeogenesis due to the high binding affinity to 
citric acid cycle enzymes, in addition to the antidiabetic activity observation from chapter 
2 and chapter 3, since the isolated compounds exhibit significant inhibition activity 
























Figure 4-4: Visual representation of levulinic acid analog on fumarase enzyme, where the binding showed at the 




















Figure 4-5:Visual representation of isolated compound SAA4 binding on the fumarase enzyme, where the binding 
showed at the formation of a hydrogen bond between the carboxylate group with the amino acid residues SER 140, 












































Figure 4-7: Visual representation of SAA3 analog on the fumarase enzyme, where the binding showed at the formation 


















Figure 4-8: Visual representation of SAA3 isolated compound from cissus rotundifolia on isocitrate dehydrogenase 
enzyme, where the binding showed at the formation of a hydrogen bonds between the methoxy group with the amino 





















Figure 4-9: Visual representation of SAA4 isolated compound from cissus rotundifolia on isocitrate dehydrogenase 
enzyme, where the binding showed at the formation of a hydrogen bond between the methoxy group with the amino 


















Figure 4-10: Visual representation of analog AN21 on malate dehydrogenase enzyme. AN21 analog formed three 
hydrogen bonds between the amide group at C-3 with the amino acid residue ASN118; in addition, two hydrogen 

























Figure 4-11: Visual representation of isolated compound SA19 on malate dehydrogenase enzyme. SA19 represents a 
hydrogen bond interaction on the malate dehydrogenase enzyme between the hydroxyl group at C-2 with the amino 






Figure 4-12: Visual representation of levulinic acid analog on isocitrate dehydrogenase enzyme, where the binding 
occurred at the formation of a hydrogen bonds between the group at C-1 and C-2 with the amino acid residues 

























Figure 4-13: Visual representation of SAA3 analog on phosphoenolpyruvate protein kinase enzyme (PECK), where the 
binding showed at the formation of a hydrogen bonds between the group at C-1 and C-3 with the amino acid residues 
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5.1 Structure elucidation NMR spectrum 
 
1H-NMR, 13C-NMR and 2D-NMR were conducted using Bruker AVANCE-400 
MHz and 600 MHz NMR spectrometer in deuterated chloroform (CDCl3) using 
tetramethylsilane (TMS) as the internal standard; chemical shifts are given in ä (ppm) 
values.  
 




Figure 5-2 : 13C -NMR Spectrum of 1 in CDCL3 
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Figure 5-3 : 1H -NMR Spectrum of 3 in CDCL3 
 









Figure 5-5 : DEPT135 -NMR Spectrum of 3 in CDCL3 
 125 
 









Figure 5-8 : DEPT90 -NMR Spectrum of 4 in Acetone 
 
